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Half-Baked: The Science and Politics of
Legal Pot
Joëlle Anne Moreno*
ABSTRACT
Weed, herb, grass, bud, ganja, Mary Jane, hash oil, sinsemilla,
budder, and shatter. Marijuana – whether viewed as a medicine or
intoxicant – is fast becoming a part of everyday life, with the CDC
reporting 7,000 new users every day and the American market projected
to grow to $20 billion by 2020. Based on early campaign rhetoric, by that
same year the U.S. could have a pro-marijuana president.
Despite its growing acceptance and popularity, marijuana remains
illegal under federal law. Like heroin, LSD, and ecstasy, marijuana is a
DEA Schedule I drug reflecting a Congressional determination that
marijuana is both overly addictive and medically useless.
So what is the truth about pot? The current massive pro-marijuana
momentum and increased use, obscures the fact that we still know almost
nothing about marijuana’s treatment and palliative potential. Marijuana’s
main psychoactive chemical is THC; but it also contains over 500 other
chemicals with unknown physiological and psychological effects that vary
based on dosage and consumption method. Medical marijuana may be
legal in 32 states and supported by 84% of Americans, but federal
constraints shield marijuana from basic scientific inquiry. This means that
lawmakers and voters are enthusiastically supporting greater access to a
drug without demanding critical scientific data. For policymaking
purposes, this data should include marijuana’s short and long-term brain
*Joëlle Anne Moreno, Professor of Law & Associate Dean for Faculty, Florida
International University College of Law, Miami, FL. My son Adam suggested I simply
dedicate this Article “to funions.” That would have been hilarious, but misleading. Kurt
Vonnegut was probably right that “alcohol and marijuana used in moderation, plus loud
usually low-class music, makes stress and boredom infinitely more bearable;” but I
personally rely on Cabernet and not cannabis. Many law professors use this space to
advertise their (one can only suspect imaginary) personal mentorship by a bevvy of famous
jurists and academics, which would have been fun to include given the topic. Instead I just
want to thank my team – Adam, his brother Nathan, and their father Ken. Work can be
interesting and useful - but you are my life.
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effects, possible lung and cardiac implications, chemical interactions with
alcohol and other drugs, addiction risks, pregnancy and breast-feeding
concerns, and the effects of secondhand smoke.
This Article treats marijuana as a significant contemporary science
and law problem. It focuses on the fundamental question of regulating a
substance that has not been adequately researched. The Article examines
the extant scientific data, deficiencies, and inconsistencies and explains
why legislators should not rely on copycat laws governing alcohol or
prescription narcotics. It also explores how marijuana’s hybrid federal
(illegality)/state (legality) raises compelling theoretical and practical
Constitutional questions of preemption, the anti-commandeering rule, and
congressional spending power. Marijuana legalization has, thus far, been
treated as a niche academic concern. This approach is short-sighted and
narrowminded. Marijuana regulation implicates the reach of national drug
policy, the depth of state sovereignty, and the shared obligation to ensure
the health and safety of our citizenry.
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I.

INTRODUCTION

In the movie This is the End (2013), a group of stoner actors gather
at James Franco’s house unaware of the impending Apocalypse which,
like all cinematic disasters, will force each of them to reconsider their life
choices and priorities.
Jay Baruchel:Can we please go to f***ing Carl’s Jr.?
Seth Rogen: Uh, I would love to, but I’m on a. . . I can’t really eat that
stuff right now. I’m on a. . . I’m on this cleanse . . . .
Jay Baruchel: So you’re not drinking, you’re not smoking weed?
Seth Rogen: Oh, no. I’m drinking, I’m smoking weed. I’m on a
cleanse, I’m not psychotic.1

In an art imitates life cinematic moment, Seth Rogen speaks for
America. Marijuana is fast becoming an essential element of everyday life.

1. THIS IS THE END (Columbia Pictures Corp. 2013); see also This Is the End –
Quotes, IMDB, https://imdb.to/2RjwQL3 (last visited Mar. 18, 2019).
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As the New York Times similarly and rather humorously reported on
June 21, 2018, “decriminalizing marijuana has left pot smoke the signature
olfactory experience of New York . . . .”2 The shift from the urban
summertime stink of rotting garbage to the urbane odor of cultivated pot
is only partly welcome. Wonder Woman, a currently trendy cannabis
strain, has been described as a powerful “mostly skunky smell with notes
of fruit and jet fuel.”3 But in New York City and elsewhere, marijuana is
now an everyday experience, even for those who follow the late First Lady
Nancy Reagan’s signature advice— “just say no.”4
A.

Introduction to Legal Pot

Marijuana legalization advocacy is at an all-time high.5 The current
public debate began in the late 1990s. Over the past three decades, prolegalization forces have persuasively argued that the advantages of
medical marijuana (e.g., potential therapeutic applications, avoiding the
prosecution of otherwise law-abiding medical users, and preventing the
disparate prosecution of minorities for low level crimes) outweigh the
disadvantages (e.g., addiction possibility, increased roads and highway
safety concerns, accidental ingestion, and potential short or long-term
psychological and/or physiological risks).
Despite widespread state legalization, marijuana’s medical potential
remains uncharted, while the enforcement of marijuana laws where pot
remains illegal is a massive, problematic, and costly undertaking. This is
especially concerning because “[o]f the 8.2 million marijuana arrests

2. Ginia Bellafante, Marijuana: The Signature Olfactory Experience of New York,
N.Y. TIMES (June 21, 2018), https://nyti.ms/2zr0ua0.
3. Id.
4. See Michael McGrath, Nancy Reagan and the negative impact of the ‘Just Say No’
anti-drug campaign, THE GUARDIAN (Mar. 8, 2016, 2:23 PM), https://bit.ly/2qu6Dvy
(arguing that the mid-80s “Just Say No” campaign was ineffective because it “aligned
‘drugs’ (non-specific in terms of type and method of ingestion) with a dangerous and
roughly defined ‘other’, and presented them as the consequence of collective personal
failure in affected communities rather than a public health crisis for millions of
Americans”); see also Scott O. Lilienfeld & Hal Arkowitz, Why “Just Say No” Doesn’t
Work, SCI. AM. MIND (Jan. 1, 2014), https://bit.ly/2gt9kNB (citing to the extensive data
“reveal[ing]that teens enrolled in the [D.A.R.E.] program [Drug Abuse Resistance
Education—a cornerstone of the “Just Say No” Prevention Program] were just as likely to
use drugs as were those who received no intervention,” while additional data demonstrates
that some D.A.R.E. programs paradoxically “backfire when it comes to the use of milder
substances, such as alcohol and cigarettes . . . [and there is even] a slight tendency for teens
who went through D.A.R.E. to be more likely to drink and smoke than adolescents not
exposed to the program” because “D.A.R.E. may inadvertently convey the impression that
alcohol and tobacco are innocuous by comparison”).
5. See Marijuana Legalization and Regulation, DRUG POL’Y ALLIANCE,
https://bit.ly/2xfjncZ (last visited Mar. 18, 2019).
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between 2001 and 2010, 88% were for simply having marijuana.6 The
American Civil Liberties Union (ACLU) reports cannabis law
enforcement costs state governments a total of $3.6 billion annually.7
Given the high cost of arresting for low-level criminality, legal marijuana
creates an irresistible win-win. Legalization offers state and local
government a path to reduce law enforcement costs while simultaneously
increasing revenue by creating new licensing, regulatory, and taxation
income streams.
Today, there may be a dispensary down the block from where you
live—but make no mistake, pot is illegal. Since 1970, Congress has
banned marijuana as a Schedule I drug under the Controlled Substances
Act (CSA).8 Schedule I drugs are illegal by definition even in the absence
of valid scientific substantiation. Marijuana’s Schedule I status is based
solely on a five-decade-old congressional finding that pot, like heroin,
LSD, and methylenedioxymethamphetamine (a.k.a. MDMA or ecstasy),
has a high potential for abuse and has no currently accepted medical use
in treatment.9 With marijuana now legal in most states, very little attention
has been paid to its Schedule I status and its implications for scientific
research.
Despite its enduring federal illegality, today pot can be legally grown,
used, bought, and sold in a growing number of states across the country.
It is possible, but far from certain, that the current massive shift to greater
6. Marijuana Arrests by the Numbers, AM. CIVIL LIBERTIES UNION
https://www.aclu.org/gallery/marijuana-arrests-numbers (last visited Mar. 18, 2019).
7. HUMAN RIGHTS WATCH & AM. CIVIL LIBERTIES UNION, EVERY 25 SECONDS: THE
HUMAN TOLL OF CRIMINALIZING DRUG USE IN THE UNITED STATES 5, 185-86 (2016)
(highlighting how U.S. drug policies affect human lives, including those charged with
criminal drug offenses relating to the possession and use of marijuana).
8. Controlled Substances Act, 21 U.S.C. §§ 801–971 (2012 & Supp. 2017). The CSA
provides that, “[e]xcept as authorized by this subchapter, it shall be unlawful for any person
knowingly or intentionally– to manufacture, distribute, or dispense, or possess with intent
to manufacture, distribute, or dispense, a controlled substance.” 21 U.S.C. § 841(a)(1). The
CSA classifies controlled substances into five schedules and marijuana is classified as a
Schedule I drug, which is the most restrictive category reserved for substances deemed to
have high abuse potential and no currently accepted medical purpose, except for
government-approved research projects. See 21 U.S.C. § 812(a)–(c); see also 21 U.S.C. §
823(f). Under the CSA, the Attorney General and Secretary of Health and Human Services
can add or remove “any drug or other substance” from the schedules. See 21 U.S.C. §
811(a)–(b).
9. 21 C.F.R. § 1308.11(b)–(d) (2018) (providing a list of current Schedule I drugs,
such as heroin, lysergic acid diethylamide (LSD), mescaline, and other hallucinogenic
amphetamine derivatives); see also 21 U.S.C. § 812(b)(1) (2018) (emphasizing that
Schedule I drugs have a “high potential for abuse . . . no currently accepted medical use in
treatment in the United States . . . [and] a lack of accepted safety for use . . . under medical
supervision”); 21 U.S.C. § 801(2) (declaring the congressional finding—as of the modern
CSA’s enactment in 1970—that controlled substances like marijuana “have a substantial
and detrimental effect on the health and general welfare of the American people.”).
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legal marijuana use could eventually provide an increased evidence base
of its effects provoking the federal government to remove current research
obstacles. In the interim, the simultaneous legality and illegality of
cannabis is unusual and intriguing. Local decriminalization clearly reflects
intrastate interests, but as marijuana momentum increases, political, legal,
and regulatory complexities transcend state line. At the same time, shifts
in federal policy and enforcement protocols (most recently and notably
between the Obama and Trump administrations) exacerbate preexisting
federal-state tensions.10 As the recent heated debate about medical
marijuana access for veterans demonstrates,11 the current delicate balance
between federal and state law and policy cannot endure. A well-publicized
February 2018 lawsuit seeking to resolve this problem through federal
legalization of marijuana was dismissed;12 but future legal tensions and
challenges are inevitable.
In the U.S., legal pot was initially only available for medical
purposes. In November 1996, California became the first state to legalize
medicinal pot when voters passed Proposition 215.13 Proposition 215
became California’s Compassionate Use Act, permitting patients (and
their primary caregivers) to possess and cultivate marijuana—with a
physician’s recommendation—for the treatment of various enumerated
disorders.14 The California law also protects physicians from legal
sanction if they recommend cannabis to their patients.15 State medical
marijuana statutes enacted after California’s typically adopt a similar
structure by insulating qualified patients and their doctors from arrest,
prosecution, and civil sanction (e.g., fines or forfeiture).16 Many state laws
also specifically permit designated caregivers to lawfully “possess, handle,
10. See infra notes 346–55 and accompanying text.
11. See Julio Ochoa, Veterans Lobby Federal Government for Medical Marijuana
Access, WBUR (Sept. 19, 2018), https://wbur.fm/2PL8byq (highlighting that veterans
around the country are calling on the federal government to reclassify marijuana to reflect
its medical value because they say that they use the drug to treat conditions from pain to
post-traumatic stress disorder).
12. Washington v. Sessions, No. 17 Civ. 5625 (AKH), 2018 WL 1114758, at *3–10
(S.D.N.Y. Feb. 26, 2018); see also Brendan Pierson, U.S. federal judge rejects challenge
to marijuana prohibition, REUTERS. (Feb. 26, 2018, 7:35 PM), https://reut.rs/2ACDFlx
(explaining that the U.S. District Court “ruled that the lawsuit must be dismissed because
the plaintiffs had failed to use administrative procedures within the Drug Enforcement
Administration (DEA) to challenge the ban,” but the decision “should not be understood
as a factual finding that marijuana lacks any medical use in the United States”).
13. Compassionate Use Act of 1996, CAL. HEALTH & SAFETY CODE § 11362.5 (West
2018) (originally enacted by California Proposition 215).
14. Id.
15. Id. § 11362.5(c).
16. Robert A. Mikos, On the Limits of Supremacy: Medical Marijuana and the States’
Overlooked Power to Legalize Federal Crime, 62 VAND. L. REV. 1421, 1430 (2009)
(discussing N.M. STAT. ANN. § 26-2B-4(A) (West 2018)).
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and even cultivate marijuana on behalf of qualified patients without fear
of state-imposed sanctions.”17 The first wave of medicinal cannabis
legalization (1996-2004) included Alaska, California, Colorado, Hawaii,
Maine, Montana, Nevada, Oregon, Vermont, and Washington.18
In 2001, the Supreme Court entered the medicinal cannabis debate.
As discussed in more detail below, in United States v. Oakland Cannabis
Buyers’ Cooperative,19 the Court rejected an argument that the California
law had effectively created a new medicinal necessity exception to the
CSA.20 Four years later, in Gonzales v. Raich,21 the Court would
specifically uphold federal CSA marijuana enforcement as a proper
exercise of Congressional Commerce Clause power.22 But Supreme Court
intervention has done nothing to ameliorate federalism tensions or slow
the tide of legalization. In the immediate wake of Raich, 32 additional
states legalized medical marijuana, bringing the current total to 32 states
plus the District of Columbia, Guam, and Puerto Rico.23 In 2014, poised
to reenter the marijuana legalization debate, the Court sidestepped a case
involving recreational use legalization.24 Nebraska and Oklahoma had
sought to enjoin Colorado from implementing its recreational use statute,
arguing that the new law “created a dangerous gap in the federal drug
control system,” and that interstate commerce was implicated because
“[m]arijuana flows from this gap into neighboring states.”25 The Court
declined to even hear the case, although Justice Thomas and Justice Alito
dissented from this decision.26
Legal pot is increasingly popular among voters. By 2018, legalization
for medical use was supported by 84% of Americans.27 That same year,
the FDA enhanced medical pot’s mainstream appeal by approving the first

17. Id. at 1431.
18. Id. at 1423 n.6; see also DRUG POL’Y ALLIANCE, supra note 5.
19. United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483 (2001).
20. Id. at 494–96.
21. Gonzales v. Raich, 545 U.S. 1 (2005).
22. Id. at 19–22.
23. See German Lopez, Marijuana is Legal for Medical Purposes in 32 States, VOX,
http://bit.ly/2RCaLYi (last updated Nov. 14, 2018) (showing the 32 states that have
legalized medical marijuana: Alaska, Arizona, Arkansas, California, Colorado,
Connecticut, Delaware, Florida, Hawaii, Illinois, Maine, Maryland, Massachusetts,
Michigan, Minnesota, Missouri, Montana, New Hampshire, Nevada, New Jersey, New
Mexico, New York, North Dakota, Ohio, Oregon, Oklahoma, Pennsylvania, Rhode Island,
Utah, Vermont, Washington, and West Virginia).
24. See generally Nebraska v. Colorado, 136 S. Ct. 1034 (2016) (No. 144, Orig.).
25. Petition for Writ of Certiorari at 3, Nebraska v. Colorado, 135 S. Ct. 2070 (Dec.
18, 2014) (No. 144, Orig.).
26. See Nebraska, 136 S. Ct. at 1034 (Thomas, J., dissenting).
27. Kevin Loria, 23 health benefits of marijuana, BUSINESS INSIDER (Mar. 7, 2018,
10:57 AM), https://read.bi/2wjbViN.
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cannabis-derived medication.28 Legalization momentum increasingly
includes support for recreational-use legalization or decriminalization.
Over the past six years, each of the first nine states to legalize medicinal
marijuana (except Hawaii) has legalized the possession of small amounts
of recreational-use cannabis. Massachusetts and the District of Columbia
have also similarly decriminalized limited recreational use.
Public support for both medical and recreational cannabis has also
started to cross party lines. The overall political popularity of cannabis
legalization is now “at the highest point in nearly five decades.”29 Over the
past decade, legal pot support has doubled. A 2017 Gallup poll revealed
that 51% of Republicans now support marijuana legalization.30 This
represents a dramatic increase from the 42% of Republicans who
expressed support in 2016.31 Although increasingly bipartisan, voter
support for legal pot remains stronger among Democrats (72%) and
independents (67%).32 In these fractious times, it is tempting to view
bipartisan support for marijuana legalization as a common shift in social
values or personal liberty. But these assumptions naïvely underestimate
the importance of marijuana money.
B.

Introduction to Marijuana Markets

The national market for legal marijuana is exceptionally strong and
expanding. Indeed, “the total estimated value of legal cannabis sales in the
United States was $5.7 billion in 2015 and $7.1 billion in 2016.”33 As trips
to the local dispensary replace trips to the local bar, states that have
legalized both medical and recreational marijuana are capitalizing on new
business, license, taxation, and other revenue opportunities.34 For
example, Colorado reported 2015 cannabis sales and tax revenue of
$88,239,323.35 Similarly, during the 2016 fiscal year, Washington state
reported “local sales taxes and state business and occupation taxes on
recreational and medical cannabis” totaling $53,410,661.36
28. Ryan Grenoble, First Cannabis-Derived Drug Approved by FDA for Medical Use,
HUFFINGTON POST (last updated June 29, 2018), https://bit.ly/2Iw37tZ.
29. Justin McCarthy, Record-High Support for Legalizing Marijuana Use in U.S.,
GALLUP (Oct. 25, 2017), https://bit.ly/2QdoXXB.
30. Id.
31. Id.
32. Id.
33. NAT’L ACADS. OF SCIS., ENG’G, & MED., THE HEALTH EFFECTS OF CANNABIS AND
CANNABINOIDS 377–378 (2017) [hereinafter THE HEALTH EFFECTS OF CANNABIS].
34. See Jeremy Berke & Skye Gould, Michigan became the 10th state to legalize
recreational marijuana. This map shows every US state where the drug is legal, BUSINESS
INSIDER (Nov. 7, 2018, 10:35 AM), https://read.bi/2E6hSmt.
35. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 378.
36. Id.
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The future of new marijuana markets is even brighter. A recent report
issued by BDS Analytics, a cannabis “business intelligence” research firm,
estimates that California (with its population of 40 million people) should
expect annual sales to hit $3.7 billion in 2018 and increase to $5.1 billion
by 2019.37 Other cannabis industry analysts have been (unsurprisingly)
equally bullish, estimating annual national marijuana sales revenue for
2017—before California legalized recreational pot—as high as $10
billion.38 On July 19, 2018, the business of marijuana first went
mainstream when Tilray (a Canadian medical marijuana company)
became the first marijuana company to go public on a major U.S. exchange
(Nasdaq).39 In December 2018, Altria (the parent company of Philip
Morris) announced a $2.4 billion investment in Cronos Group (a medical
and recreational marijuana company based in Canada).40
Marijuana market increases reflects a rapidly growing consumer
base. Marijuana is now the most-used illicit drug and national
consumption rates for all cannabis products are rising rapidly. In 2017,
more than 11 million adults in the U.S. ages 18-25 smoked, vaped, or ate
marijuana.41 Over the past decade, annual U.S. cannabis use has increased
from 10.88% among Americans age twelve and older (2008–2009) to
13.71% (2015–2016).42 In contrast, over the same seven-year period,
annual cocaine use decreased from 2.01% to 1.84%, tobacco use declined
from 28.06% to 23.72%, and alcohol use remained virtually constant,
shifting just slightly from 51.74% to 51.21%.43 In 2016, the Centers for
Disease Control and Prevention (“CDC”) reported that 2.5 million
Americans annually start using marijuana, a daily average of
37. Jeremy Berke, California’s cannabis market is expected to soar to $5.1 billion —
and it’s going to be bigger than beer, BUSINESS INSIDER (Feb. 28, 2018, 11:30 AM),
https://read.bi/2DPBnio.
38. Jeremy Berke, The legal marijuana market is exploding — it’ll hit almost $10
billion sales in this year, BUSINESS INSIDER (Dec. 8, 2017, 3:46 PM),
https://read.bi/2F35BDy.
39. Chloe Aiello & Kellie Ell, Tilray joins Nasdaq in first US cannabis IPO, CNBC
(July 23, 2018, 2:28 PM), https://cnb.cx/2JEeh0i; see also Gene Johnson, Canadian
marijuana company has first US marijuana IPO, MERCURY NEWS (July 20, 2018, 12:01
PM), https://bayareane.ws/2LHlyy2 (“Tilray isn’t the first pot company to trade on a major
American stock exchange, but it is the first to do so with an IPO, a step that could boost
credibility and confidence in the industry . . . .”).
40. Marlboro maker Altria buys big stake in Canadian marijuana company, CBS
NEWS (Dec. 7, 2018, 9:55 AM), https://www.cbsnews.com/news/altria-marlboro-makerbuys-big-stake-in-cronos-canadian-marijuana-company/.
41. DrugFacts: What is marijuana?, NAT’L INST. ON DRUG ABUSE,
https://bit.ly/1QbDwb4 (last updated June 2018).
42. National Survey on Drug Use and Health: Comparison of 2008–2009 and 2015–
2016 Population Percentages, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN.,
https://bit.ly/2jT6nGl (last visited Mar. 18, 2019) [hereinafter National Survey on Drug
Use].
43. Id.
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approximately 7,000 new marijuana users.44 The National Institute for
Drug Abuse (“NIDA”)45 is the research branch of the National Institutes
of Health (“NIH”). 46 NIDA, which is dedicated to “advanc[ing] science on
the causes and consequences of drug use and addiction and to apply[ing]
that knowledge to improve individual and public health,”47 estimates that
22.2 million Americans use marijuana each month.48 Despite its rapid
growth, some facts about marijuana use remain constant. For example,
men are much more likely to use marijuana than women—and this gender
gap has recently expanded.49
Growing marijuana support, markets, and consumption are a global
phenomenon. According to the World Health Organization (“WHO”), the
annual rate of marijuana consumption worldwide is approximately 147
million individuals or nearly 2.5% of the global population.50 For example,
as of April 2017, Iceland reported the highest rate of cannabis use (18.3%
of the population), with Nigeria (14.2%of the population), Canada (12.7%
of the population), New Zealand (11% of the population), and Spain (9.2%
of the population) also reporting significant consumption rates.51 Medical
marijuana is currently legal in Canada, Australia, the Netherlands, France,
Uruguay, Romania, Chile, the Czech Republic, Columbia, and Jamaica.52
Marijuana is the third most commonly used recreational drug worldwide,
following alcohol and tobacco.53

44. Alejandro Azofeifa et al., National Estimates of Marijuana Use and Related
Indicators—National Survey on Drug Use and Health, United States, 2002–2014,
MORBIDITY & MORTALITY WKLY. REP. SURVEILLANCE SUMMARIES, Sept. 2, 2016, at 1, 1,
http://bit.ly/2GeopQN.
45. See NAT’L INST. ON DRUG ABUSE, https://bit.ly/1MNlOtZ (last visited Mar. 18,
2019).
46. See NIH Organization, NAT’L INSTS. OF HEALTH, https://bit.ly/2iaGL8O (last
visited Dec. 11, 2018).
47. National Institute on Drug Abuse (NIDA), NAT’L INSTS. OF HEALTH,
https://bit.ly/2Ifv75M (last updated Nov. 28, 2018).
48. NAT’L INST. ON DRUG ABUSE, MARIJUANA RESEARCH REPORT 7,
http://bit.ly/2Pyw8Zj (last updated June 2018) [hereinafter NIDA, MARIJUANA].
49. Id.
50. Mary Barna Bridgeman et al., Medicinal Cannabis: History, Pharmacology, And
Implications for the Acute Care Setting, 42 PHARMACY & THERAPEUTICS 180, 180 (2017).
51. Gavin Haines, Mapped: The Countries that Smoke the Most Cannabis, THE
TELEGRAPH (Apr. 20, 2017, 1:00 PM), http://bit.ly/2zTsnJ7.
52. Sean Williams, 10 Countries (Aside from the U.S.) Where Some Form of Medical
Marijuana is Legal, MOTLEY FOOL (May 15, 2016), http://bit.ly/2RToWsC.
53. LESLIE L. IVERSEN, THE SCIENCE OF MARIJUANA 188 (2d ed. 2008).
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Introduction to Cannabis Science

Despite widespread and growing use, we do not know if marijuana is
efficacious or safe.54 In the 1970s, when the federal government deemed
marijuana to be as addictive and medically useless as heroin, LSD, and
methylenedioxymethamphetamine (ecstasy) by making it a Schedule I
drug, the DEA effectively blocked scientific research.55 State legalization
efforts typically ignore the paucity of the scientific evidence and do not
seek Schedule I removal. This makes sense because neither legislators nor
pro-marijuana voters would benefit from new information about health
risks and the lack of evidence of health benefits has not diminished
marijuana’s growing appeal. Over the past half-century, as cannabis use
has grown and botanical geneticists continue to tinker with its chemical
components, scientists’ efforts to understand how currently available
marijuana products affect the human brain and body have been stymied.
As a result, we find ourselves with a drug in everyday use but an
inadequate body of scientific evidence to understand its myriad potential
risks including: short and long-term brain effects (including potential
effects on the developing brain); lung-health and/or cardiac implications;
chemical interactions with alcohol and other legal and illegal drugs;
fertility, safe pregnancy and/or breastfeeding concerns; and exposure to
secondhand marijuana smoke.56

54. There are “potentially severe cognitive, psychotomimetic, and substance abuserelated adverse effects associated with Δ9-tetrahydrocannabinol (THC) exposure that must
be taken seriously, especially in young or cannabis-naïve patients.” Perry G. Fine & Mark
J. Rosenfeld, The Endocannabinoid System, Cannabinoids, and Pain, RAMBAM
MAIMONIDES MED. J., Oct. 2013, at 1, 4, http://bit.ly/2PySmun (noting that “fatalities have
not been reported directly related to the toxicity of any cannabinoid, even with extremely
high dosing”); see also Loria, supra note 27 (“More research would also shed light on the
risks of marijuana. Even if there are legitimate uses for medicinal marijuana, that doesn’t
mean all use is harmless.”).
55. Loria, supra note 27 (“[S]cientists say that limitations on marijuana research mean
we still have big questions about its medicinal properties. In addition to CBD and THC,
there are another 400 or so chemical compounds, more than 60 of which are cannabinoids.
Many of these could have medical uses. But without more research, we won’t know how
to best make use of those compounds.”); Cannabis and Cannabinoids (PDQ)–Health
Professional Version: General Information, NAT’L CANCER INST., http://bit.ly/2RQL86L
(last updated Aug. 16, 2018) (noting that any scientist seeking to engage in clinical
cannabis research in the United States must “file an Investigational New Drug (IND)
application with the FDA, obtain a Schedule I license from the U.S. Drug Enforcement
Administration, and obtain approval from the National Institute on Drug Abuse”).
56. Charles W. Webb & Sandra M. Webb, Therapeutic Benefits of Cannabis: A
Patient Survey, 73 HAW. J. MED. PUB. HEALTH 109, 109 (2014) (noting that “[c]linical
research regarding the therapeutic benefits of cannabis (“marijuana”) has been almost nonexistent in the United States since cannabis was given Schedule I status in the Controlled
Substances Act of 1970”).
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The federal government’s Schedule I stranglehold is not a complete
ban; but it has significantly hindered the development of meaningful
widespread research. For example, only 11 marijuana studies were
authorized from 2000 to 2009.57 To make matters worse, NIDA,58 which
must approve all cannabis research,59 restricts all research to a single strain
of research-grade pot grown only at the University of Mississippi. NIDA
provides authorized labs only with what has been described as a
“micronized powder” form of this Mississippi-grown cannabis.60
Unsurprisingly, researchers regularly complain that this powdered pot is
an extremely poor analog for the wide range of cultivated, dispensaryavailable products.61
If the research to date reveals anything about the pharmacology of
marijuana, we know that it is extremely complex. Pot’s main
psychoactive chemical is delta-9-tetrahydrocannabinol (“THC”), but it
also contains over 500 other chemicals with virtually unknown properties
and effects.62 Without a solid foundational understanding of pot’s
chemical composition, we cannot reliably measure the impact of basic
scientific variables including: (1) the ever-expanding variety of delivery
methods (e.g. smoking, vaping, edibles); (2) THC and other chemical
potency variations; (3) physiological and psychological distinctions
57. Id.
58. Mikos, supra note 16 at 1433–34.
59. In fiscal year 2017, the NIH through NIDA “supported 330 projects totaling
almost $140 million on cannabinoid research.” NIH Research on Marijuana and
Cannabinoids, NAT’L INST. ON DRUG ABUSE, http://bit.ly/2C51Gmf (last updated May
2018); see also Estimates of Funding for Various Research, Condition, and Disease
Categories (RDC), NAT’L INST. ON DRUG ABUSE (May 18, 2018),
https://report.nih.gov/categorical_spending.aspx.
60. THE HEALTH EFFECTS OF CANNABIS, supra note 33, ch. 15 (noting that, “[b]ecause
of restrictions on production and vicissitudes in supply and demand, federally produced
cannabis may have been harvested years earlier, is stored in a freezer (a process that may
affect the quality of the product).”).
61. Caleb Hellerman, Scientists Say the Government’s Only Pot Farm Has Moldy
Samples—and No Federal Testing Standards, PBS NEWS HOUR (Mar. 8, 2017, 3:55 PM),
https://to.pbs.org/2GcrJfp (citing researchers’ concerns that pot ordered for research
purposes “didn’t resemble cannabis” and “didn’t smell like cannabis,” and that some
“samples were contaminated with mold, while others didn’t match the chemical
potency . . . requested for the study”); Tom Hesse, Weak Weed and Red Tape: Marijuana
Research is Slow Going, CHRON. HIGHER EDUC. (Feb. 28, 2017),
https://www.chronicle.com/article/Weak-WeedRed-Tape-/239328 (citing concerns that
“the cannabis strain that Mississippi has been providing is so low in THC . . . it’s not really
possible to do actual use-patterns analysis . . . . [N]o one uses that. Everyone’s been using
really powerful stuff.”); Sara Reardon, Marijuana gears up for production high in US labs,
519 NATURE 269, 269–70 (2015); Sarah See Stith & Jacob Miguel Vigil, Federal barriers
to cannabis research, 352 SCIENCE 1182, 1182 (2016).
62. Hellerman, supra note 61; see also MARTIN BOOTH, CANNABIS: A HISTORY 5–6
(2004) (noting that, “[o]f the approximately 460 known chemical constituents of cannabis,
more than sixty have the molecular structure of a cannabinoid . . . .”).
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between habitual and occasional users; (4) user age differences; (5)
second-hand effects; and/or (6) drug and alcohol interactions. The paucity
of the current evidence base has been specifically criticized by the WHO,
which recently opined that “more research is needed on the basic
neuropharmacology of THC and other cannabinoids.”63
In this scientific evidence void, our continued reliance on copycat
laws borrowed from regulations governing alcohol or other drugs (such as
opioids) is inherently suspect. Different intoxicants have distinct chemical
properties and effects, most notably alcohol’s steady metabolism rate
(which provides lawmakers with an empirically accurate base for
extrapolating an impairment timeline)64 and the chemical consistency of
prescription narcotics. Cannabis impairment assessment, which I intend to
address in a forthcoming companion article, is especially tricky because
we have limited data on the measurement of cannabinoids in various
bodily fluids, no scientific consensus on the correlation of cannabinoid
levels to impairment effects (i.e., human judgment, motor coordination,
and reaction time), and no agreement on valid roadside measurement
methods or devices.
D.

Introduction to the Politics of Legalization

Legalizing pot, before we have begun to understand its potential
psychopharmacological and physiological effects, is a public health and
policy problem because it is “counterintuitive to the mission of our
governmental agencies.”65 To make evidence-based decisions,
policymakers first need “clinical researchers to acquire safety and efficacy
data on products in the marketplace.”66 But even accurate scientific
information cannot always steer public policy in a climate of divisive and
inconsistent party politics. As discussed below, the Obama and Trump
administrations may have differed on the enforcement of criminal
sanctions, but they both have ignored the recommendation of the
American Medical Association to remove marijuana from Schedule I to
permit clinical research and facilitate the development of new cannabis-

63. Cannabis, WORLD HEALTH ORG., http://www.who.int/substance_abuse/
facts/cannabis/en/ (last visited Mar. 18, 2019) [hereinafter WHO, Cannabis].
64. Marijuana Research: Frequently Asked Questions, UNIV. OF MISS.,
https://pharmacy.olemiss.edu/marijuana/ (last visited Mar. 18, 2019).
65. Summary of Request for Information (RFI) Regarding Varieties of Marijuana and
Marijuana Products for Research, NAT’L INST. ON DRUG ABUSE, http://bit.ly/2Qxz3a0 (last
updated Nov. 2016) [hereinafter NIDA, Summary of RFI].
66. Id.

414

PENN STATE LAW REVIEW

Vol. 123:2

derived medicines.67 State legalization provides marijuana to the people,
but does nothing to advance the science.
The messy politics of marijuana science transcends the partisan
divide. “Post-truth” America has an increasingly uncomfortable
relationship with science, evidence, and facts. Stephen Colbert introduced
the word “truthiness,” into the vernacular in 2005—deftly capturing the
political zeitgeist of an American public increasingly “divided between
those who think with their head and those who know with their heart.”68
More recently, cognitive scientists Hugo Mercier and Dan Sperber suggest
that facts are decreasingly important, not merely because human ability to
reason is inherently flawed; but because we increasingly use reason
principally to critique the ideas of others.69 Reason serves just two
functions, “that of producing reasons for justifying oneself, and that of
producing arguments to convince others.”70 The current perfect storm of
scientific ignorance, empirical relativism, and (if Mercier and Sperber are
correct) the diminished role of reason, impacts all law and science
questions—from global climate change and environmental safety to
intimate questions of reproductive health.71 Although legal marijuana may
draw bipartisan support,72 voters’ and legislators’ common ground on a
highly lucrative new local market does not demonstrate values-based
bipartisan agreement or a shared commitment to evidence-based public
policy.
A truthiness approach to marijuana legalization also fits with our
increasing about basic science. In surveys conducted over the past decade,
Americans consistently reveal a shocking unfamiliarity with middleschool level scientific facts and methods. Among adults, 53% do not know
how long it takes for the earth to revolve around the sun, 41% believe that
humans and dinosaurs lived together at the same time, and 47% cannot
even roughly approximate how much of the earth’s surface is covered with

67. See COUNCIL ON SCI. & PUB. HEALTH, AM. MED. ASS’N, REP. NO. 3-I-09, USE OF
CANNABIS FOR MEDICINAL PURPOSES 2 (2009), http://bit.ly/2B9CXeJ.
68. SOPHIA A. MCCLENNEN, COLBERT’S AMERICA: SATIRE AND DEMOCRACY 123
(2011) (ebook).
69. HUGO MERCIER & DAN SPERBER, THE ENIGMA OF REASON 7–11 (2017).
70. Id. at 8.
71. Andrew Sullivan, When Two Tribes Go to War, N.Y. MAG. (Feb. 2, 2018, 9:35
AM), https://nym.ag/2PuITUV.
72. Astead W. Herndon, Meet Colorado’s New Single-Issue Voters: The Cannabis
Community, N.Y. TIMES (June 25, 2018), https://nyti.ms/2LaxgSo (“In the 2018 midterm
elections, [cannabis] industry leaders are hoping that the spread of marijuana legalization
will lead to the birth of a new single-issue voter: People who, like some Medicare recipients
or gun owners, are motivated to cast ballots based on the benefits they have received or
fears about any government rollback of access.”).
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water.73 Under these circumstances, it is not surprising that marijuana
proponents appear uninterested in the science. Scientific ignorance and
disinterest, a growing disinclination to question our own beliefs, and
instant access to all sorts of scientific-sounding information on the internet
are a toxic combination that is “dramatically reshap[ing] our relationship
to the world of knowledge” by “unmoor[ing] information from the context
required to understand it.”74 The regular consumption of partisan
information (whether on Facebook, Breitbart, or CNBC) without debate
or context has been shown to exacerbate critical reasoning deficits on all
evidence-based questions—even those seemingly unrelated to party
politics.75
E.

Why the Science and Politics of Legal Pot Matters

According to the philosopher Susan Haack, “[t]he core
epistemological values of science are rooted in the central, defining
concern of inquiry generally: finding things out.”76 Science invariably
works within society, but when the surrounding culture works to
“undermine the norms of evidence sharing and respect for evidence, or . . .
erode or compromise them, the integrity of science comes under threat.”77
But even if we could overcome truthiness obstacles, because the marijuana
movement is driven by users and profit-seeking legislators, proponents
have no reason to advocate for better scientific research. If medical and/or
psychological risks are real, these will only create impediments. But the
paucity of the medical evidence is a critical legal and policy problem.
Without more comprehensive information on the health benefits and
palliative effects of marijuana, doctors, lawmakers, voters, and consumers
cannot make scientifically sound decisions. The current “lack of evidencebased information on the health effects of cannabis and cannabinoids

73. American Adults Flunk Basic Science, SCIENCEDAILY (Mar. 13, 2009),
http://www.sciencedaily.com/releases/2009/03/090312115133.htm.
74. SETH MNOOKIN, THE PANIC VIRUS 5–8 (2011) (describing the promulgation of the
increasingly popular and dangerous myth that MMR vaccines cause autism).
75. Jeff Cirillo, Warren, Gardner Unveil Marijuana Bill Easing Federal Enforcement,
ROLL CALL (June 7, 2018, 2:11 PM), http://bit.ly/2RN0KrY. But see ANDREW GUESS ET
AL., KNIGHT FOUND., AVOIDING THE ECHO CHAMBER ABOUT ECHO CHAMBERS: WHY
SELECTIVE EXPOSURE TO LIKE-MINDED POLITICAL NEWS IS LESS PREVALENT THAN YOU
THINK (Feb. 2018), http://bit.ly/2rzytK5 (concluding that “there is diversity in the sources
and media outlets to which people pay attention,” that many people “only pay attention to
politics at critical moments, or hardly at all,” and that “[e]ndorsements from friends on
social media and algorithmic rankings can influence the information people consume, but
these effects are more modest and contingent than many assume”).
76. Susan Haack, The Integrity of Science: What it Means and Why it Matters, 11
COLECÇÃO BIOÉTICA 9, 10 (2006) (Portugal), http://perma.cc/B9M7-2AD2.
77. Id.
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[itself] poses a public health risk”78 with significant and immediate legal
and regulatory ramifications.
This Article tackles the science and politics of legal pot. As an inquiry
into basic principles, it specifically rejects the currently faddish
“unintended consequences” legal academic lens. A quick look at Westlaw
reveals that, in this context, these unintended consequences approach has
spawned myriad academic “what if” prognostications relating to
regulatory problems of varying interest and importance (e.g., employment,
expungement, land use, trademark and zoning problems). This Article
refocuses on the fundamental legal, political and practical meaning of
increasing public access to a chemical substance we have not, and
currently cannot, properly research. The goals are to explore the basic
science of marijuana, to explain why gathering more evidence is essential
to a legitimate regulatory scheme, and to expose the current legal and
political obstacles to better science and better public health policy
decisions.
The Article is organized as follows. Part I explains the cannabis
basics—describing what marijuana is, where it comes from, and how it is
used medically and recreationally. Part II provides a user-friendly guide to
the current state-of-the-science of marijuana highlighting the Rumsfeldian
“known unknowns” and “unknown unknowns,”79 including marijuana’s
medical potential and its short and long-term psychopharmacological
effects. Part III explores the evolving law of marijuana—briefly
examining the relevant Constitutional questions including federal-state
preemption, the Commerce Clause, the Tenth Amendment’s AntiCommandeering doctrine, and congressional funding power. Finally, Part
IV anticipates the future of legal pot and predicts that the current
simulacrum of bipartisanship does not reflect actual shared understanding
and cannot insulate marijuana from our increasingly tribalized and
scientifically ignorant approach to all evidence-based questions of law and
policy.
II.

THE BASICS

A.

The History of Marijuana

According to the National Institute on Drug Abuse [NIDA],
Marijuana—also called weed, herb, pot, grass, bud, ganja, Mary Jane,
and a vast number of other slang terms—is a greenish-gray mixture of
the dried flowers of Cannabis sativa [and] some people smoke
78. THE HEALTH EFFECTS OF CANNABIS, supra note 34, ch. 15.
79. David A. Graham, Rumsfeld’s Knowns and Unknowns: The Intellectual History
of a Quip, THE ATLANTIC (Mar. 27, 2014), http://bit.ly/2LdA553.
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marijuana in hand-rolled cigarettes called joints; in pipes, water pipes
(sometimes called bongs), or in blunts (marijuana rolled in cigar
wraps).80

Cannabis is the generic name for hemp. The precise etymology of
“marijuana” is unknown, but it has been traced to an Aztec slang word for
“brothel.”81
The geographic origin of marijuana is also unknown, although most
studies suggest that it probably evolved in central Asia.82 Cannabis use has
a very long history, and we can (somewhat) reliably trace its origins to the
ancient world. A 2017 meta-analysis of marijuana’s history and
pharmacology reports that cannabis was first described “more than 5,000
years ago in what is now Romania,” but the first direct evidence of use
(THC found in ashes) dates to 400 A.D.83 Cannabis use in the U.S. began
during the 19th and early 20th centuries. Marijuana was legal to grow and
consume until the 1910s, when states first began criminalize the drug.84
But starting in the 1930s, “every state . . . banned the cultivation,
distribution, and possession of marijuana for non-medical purposes.”85
The first federal restrictions appeared in the 1937 Marihuana Tax
Act.86 Additional efforts to control marijuana were included in the Boggs
and Narcotic Control Acts of 1951 and 1956 and in the 1970 Controlled
Substances Act (“CSA”).87 As noted above, a half century ago the CSA
classified marijuana as a Schedule I drug based on a congressional finding
that pot has no possible acceptable medical use. This legislative
presumption has precluded robust scientific research on marijuana’s
effects and continues (confusingly) to make pot illegal under federal law,
in every state where it has been legalized.
Marijuana was initially criminalized for highly problematic political
and social reasons. The racist and xenophobic origins of the mid-twentieth
century marijuana prohibition movement are well documented.88 Early
cannabis criminalization coincided with an influx of Mexican immigrants

80. NIDA, MARIJUANA, supra note 48, at 5.
81. Id.
82. BOOTH, supra note 62, at 2–3.
83. Bridgeman et al., supra note 50, at 180.
84. Erwin Chemerinsky et al., Cooperative Federalism and Marijuana Regulation, 62
UCLA L. REV. 74, 81 (2015).
85. Robert A. Mikos, On the Limits of Supremacy: Medical Marijuana and the States’
Overlooked Power to Legalize Federal Crime, 62 VAND. L. REV. 1421, 1427 (2009).
86. Id.
87. Id.; Chemerinsky et al., supra note 84, at 80 (“It has been well documented that
the move to regulate marijuana was motivated in large part by racism and xenophobia.”).
88. Alex Halperin, Marijuana: Is It Time to Stop Using a Word With Racist Roots?,
THE GUARDIAN (Jan. 29, 2018, 5:00 AM), http://bit.ly/2Quxidy.
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to the U.S. at the turn of the last century.89 As Harry Anslinger,
Commissioner of the Federal Bureau of Narcotics from 1930-1962,
infamously asserted in a tirade against the drug: “There are 100,000 total
marijuana smokers in the US, and most are Negroes, Hispanics, Filipinos
and entertainers. Their Satanic music, jazz and swing result from
marijuana use. This marijuana causes white women to seek sexual
relations with Negroes, entertainers and any others.”90 This shameful past
has prompted some legalization proponents to propose that the name
“marijuana” be abandoned to better distance the drug from its shameful
past.91
Modern cannabis originated in the 1970s in California “when
professional breeders began to select the most potent, THC-rich plants for
the first time.”92 Before modern cultivation, most marijuana was imported
as “hashish resin, made of mixed populations of plants from parts of Asia,
Africa, and the Caribbean, containing varying amounts of both CBD and
THC.”93 A half-century ago, almost all of the marijuana consumed in the
United States was imported, but over the past few decades, this has
changed dramatically.94 Today we see a near-complete shift to Americangrown marijuana, with California growing 80% of the cannabis consumed
across the U.S.95 The 50 year-old movement towards domestic marijuana
coincides with significant horticultural and genetic advances as U.S.
growers began “selectively breeding THC-rich plants . . . in the quest to
make ever stronger cannabis.”96 These efforts have been wildly successful,
resulting in scientific consensus that deliberate new horticultural methods
have caused a significant rise in THC levels in cultivated marijuana.97
B.

Modern Marijuana

Marijuana is currently available in a wide variety of strains and
incorporated into a range of products. Different cannabis strains “have
89. Alyssa Pagano, The Racist Origins of Marijuana Prohibition, BUS. INSIDER (Mar.
2, 2018, 10:57 AM), https://read.bi/2QTBMu0.
90. Id.
91. Halperin, supra note 88.
92. Tom Ireland, The new strain of cannabis that could help treat psychosis, THE
GUARDIAN (Nov. 15, 2014, 7:04 PM), https://www.theguardian.com/society/
2014/nov/16/new-strain-cannabis-treat-psychosis-schizophrenia-gw-pharmaceuticalsdavid-potter.
93. Id.
94. Emily Brady, How Humboldt Became America’s Marijuana Capital, SALON (June
30, 2013, 4:30 PM), http://bit.ly/2Bdi967.
95. Id.
96. Ireland, supra note 92; see also Brady, supra note 95. See generally Zlatko
Mehmedic et al., Potency Trends of Δ9-THC and Other Cannabinoids in Confiscated
Cannabis Preparations from 1993 to 2008, 55 J. FORENSIC SCI. 1209 (2010).
97. Mehmedic et al., supra note 96, at 1216.
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varying chemical components.”98 In addition to different strains,
marijuana is also available in a variety of forms, including sinsemilla, an
especially potent variety derived from specially tended female plants, and
concentrated resins such as hash oil, budder, and shatter.99 For-profit
marijuana analytics companies currently help sellers and buyers
differentiate among strains and products. According to a recent Wired
magazine investigative report, pot labs now use “analytical chemistry”
(and crowd-sourced reviews) to “quantify 27 of the most prominent of
these flavorful, experience-defining molecules.”100
Legitimate cannabis genetic research could have significant
implications for better understanding pot’s medicinal and palliative
potential and its psychopharmacological effects. But horticultural
geneticists complain that their work is impeded by pot’s Schedule I status.
Unlike “[e]very other commercially important agricultural plant in the
world [which] has had a ton of research done on it,” marijuana “has so
much variation, and nobody knows what that variation’s all about.”101
Plant biologists cannot research the basic bases for genetic differences,
which is “what you need if you plan to breed scientifically, to enhance the
qualities the market might pay for,”102 despite the fact that more genetic
data would also be useful for medical research because different chemicals
“ameliorate clinical symptoms differently.”103 Ironically, cannabis
cultivators seeking solely to enhance THC psychoactivity have
compounded these problems. By crossbreeding to achieve the goal of
stronger marijuana, modern marijuana farmers inadvertently create
genetic sequencing complications by developing strains with multiple
copies of the gene that synthesizes THC.104

98. Janet Wells, Dazed and Confused: Marijuana Legalization Raises the Need for
More Research, UNIV. OF CAL. S.F. (June 20, 2017), http://bit.ly/2rAVb4h.
99. NIDA, MARIJUANA, supra note 48, at 5.
100. Katie M. Palmer, A New Crop of Marijuana Geneticists Sets Out to Build Better
Weed, WIRED (Apr. 20, 2016, 7:00 AM), https://www.wired.com/2016/04/the-science-ofmarijuana/.
101. Id. (quoting Reggie Gaudino, Vice President of Scientific Operations at Steep Hill,
a marijuana analytics company).
102. Id.
103. Wells, supra note 98.
104. Neel V. Patel, Cannabis gets its high-inducing power from ancient viruses,
POPULAR SCIENCE (Nov. 30, 2018), https://www.popsci.com/ancient-viruses-cannabisgenome.
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How Does Marijuana Work?
1. Cannabinoids

The cannabis plant “produces a resin containing psychoactive
compounds called cannabinoids, in addition to other compounds found in
plants, such as terpenes and flavonoids.”105 In the cannabis plant, “[t]he
highest concentration of cannabinoids is found in the female flowers.”106
More specifically, “cannabinoid” describes “a pharmacological class
of about 60 naturally occurring compounds (phytocannabinoids) found in
plants of the genus Cannabis (i.e. marijuana and hemp) and structurally
related synthetic analogues.”107 Cannabinoids are biochemically
significant because these are the “chemicals that act on the brain’s
cannabinoid receptors, part of a system that regulates a variety of
physiological processes including pain sensation, mood, memory and
appetite.”108 To date, over 100 cannabinoids have been identified.109 Pot’s
main psychoactive cannabinoid is THC.110 THC levels have varied widely
over time and continue to vary among different products. For example,
fifteen years ago “the average THC content in weed was about 3 percent
by weight.”111 Today, THC “levels top out at a whopping 37 percent.”112
In addition to THC, pot “contains more than 500 other chemicals,
including more than 100 compounds that are chemically related to
THC.”113
The basic biochemical explanation for how THC affects the brain
begins with cannabinoid receptors, which are located “in many key
regions, including the amygdala (responsible for processing memory and
emotional reactions) as well as the basal ganglia and cerebellum
(responsible for motor control, among other things).”114 Cannabinoid
receptors also exist throughout the brain and body within cell membranes
and control a host of physiological and psychological functions.115 THC

105. NAT’L CANCER INST., supra note 55.
106. Id.
107. Fine & Rosenfeld, supra note 54.
108. Ireland, supra note 92.
109. Mahmoud A. ElSohly & Waseem Gul, Constituents of Cannabis
Sativa, in HANDBOOK OF CANNABIS 3 (Roger Pertwee ed., 2014).
110. NAT’L CANCER INST., supra note 55.
111. Palmer, supra note 100.
112. Id.
113. NIDA, MARIJUANA, supra note 48, at 5.
114. Clay Dillow, How Will Police Regulate Stoned Driving?, POPULAR SCIENCE (June
4, 2013), https://www.popsci.com/science/article/2013-05/now-recreational-marijuananow-legal-two-states-how-will-police-regulate-stoned-driving.
115. See Megan Scudellari, Your Body is Teeming with Weed Receptors, THE SCIENTIST
(July 17, 2017), http://bit.ly/2rxwyWt.
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has psychoactive effects because it alters the chemical messages sent to
specific brain areas, including those that “regulate appetite, memory, fear
extinction, motor responses, and posture such as the hippocampus, basal
ganglia, basolateral amygdala, hypothalamus, and cerebellum.”116
2. The Endocannabinoid System
Although THC does not occur naturally in the body, THC acts
directly on the entire endocannabinoid system (“ECS”), which is
comprised of “cannabinoid receptors along with ‘endogenous
cannabinoids (endocannabinoids)[] and the enzymes responsible for the
synthesis and degradation of the endocannabinoids.”117 Because the
chemical structure of THC is very similar to the brain
chemical anandamide, which binds to THC receptors,118 the body
‘recognize[s] THC and [allow it] to alter normal brain communication.”119
These alterations are not just psychoactive, but can include effects on
appetite, pain, motor-learning, and inflammation because the ECS “is a
widespread neuromodulatory system that plays important roles in central
nervous system [(CNS)] development, synaptic plasticity, and the
response to endogenous and environmental insults.”120 Endocannabinoids,
which our bodies make naturally, ”function as neurotransmitters because
they send chemical messages between nerve cells (neurons) throughout
the nervous system. They affect brain areas that influence pleasure,
memory, thinking, concentration, movement, coordination, and sensory
and time perception.”121 THC is considered an exogenous cannabinoid
(phytocannabinoid) because the body does not make it, but THC has a
similar ability to stimulate neural receptors.122

[R]ecent work has provided evidence that the endocannabinoid system . . . isn’t
exclusive to the brain. It is present everywhere in the body that scientists have
looked: the heart, liver, pancreas, skin, reproductive tract, you name it. And
disrupted endocannabinoid signaling has been associated with many disorders,
including diabetes, hypertension, infertility, liver disease, and more. “There is so
much that’s still unknown about this system. It looks to be regulating every
physiological system in the body.”
Id. (quoting Nick DiPatrizio, Assistant Professor at U.C. Riverside, School of Medicine).
116. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 46–47.
117. Hui-Chen Lu & Ken Mackie, An Introduction to the Endogenous Cannabinoid
System, 79 BIOLOGICAL PSYCHIATRY 516, 516 (2016).
118. NIDA, MARIJUANA, supra note 48, at 9.
119. Id.
120. Lu & Mackie, supra note 117, at 516.
121. NIDA, MARIJUANA, supra note 48, at 9.
122. See Flora E. Kovacs et al., Exogenous and Endogenous Cannabinoids Suppress
Inhibitory Neurotransmission in the Human Neocortex, 37 NEUROPSYCHOPHARMACOLOGY
1104, 1104
(2012).
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How is Marijuana Used?
1. Cannabis Products

Marijuana is—roughly speaking—used for two different purposes:
(1) medicinal treatment and palliative care for a wide range of disorders
and conditions, and (2) fun.
Medicinal marijuana users and recreational users typically fit
different profiles. Medical users are often older (typically middle-aged)
and are frequently diagnosed with debilitating illnesses (such as cancer),
neurological or musculoskeletal problems, or chronic infections.123
Marijuana’s medical potential is discussed in more detail below, but access
to both medical and recreational marijuana is limited to those who can
afford to pay out of pocket, because even in states where medical
marijuana has been legalized, marijuana is a cash-only business with no
possibility of insurance coverage.
Medicinal and recreation cannabis is consumed in a variety of ways.
These include smoking or inhaling from cigarettes (joints), pipes
(bowls), water pipes (bongs, hookahs), and blunts (cigars filled with
cannabis); eating or drinking food products and beverages; or
vaporizing the product. These different modes are used to consume
different cannabis products, including cannabis “buds” (dried cannabis
flowers); cannabis resin (hashish, bubble hash); and cannabis oil
(butane honey oil, shatter, wax, crumble).124

The dizzying array of marijuana consumption options can have a distinct
psychopharmacological impact.
2. Consumption Methods
Whether one uses pot as a medicine or for recreation, the choice of a
particular method of marijuana consumption “impact[s] the onset,
intensity, and duration of psychoactive effects; effects on organ systems;
and the addictive potential and negative consequences associated with
use.”125 NIDA reports that vaping is increasingly popular.126 This may be
attributable to the fact that “[v]aporization provides effects similar to
smoking while reducing exposure to the byproducts of combustion and
possible carcinogens and decreasing adverse respiratory syndromes.”127
123. See Alice Robb, This Is What the Average Medical Marijuana User Looks Like,
NEW REPUBLIC (Jan. 9, 2014), http://bit.ly/2UIFshh.
124. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 50.
125. Bridgeman et al., supra note 50, at 182.
126. NIDA, MARIJUANA, supra note 48, at 5.
127. Bridgeman et al., supra note 50, at 182.
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When cannabis is smoked or vaped, THC rapidly diffuses to the brain,
eliciting a perceived high within seconds or minutes, reaching a peak after
about 30 minutes, and subsiding within 2 to 3 hours.128 “‘Dabbing,’ a term
for flash-vaporizing butane hash oil-based concentrates, has been reported
to offer a different and stronger intoxicating effect than smoking/
vaping.”129 Whether marijuana is smoked, vaped, or dabbed, “THC and
other chemicals in the plant pass from the lungs into the bloodstream,
which rapidly carries them throughout the body to the brain. The person
begins to experience effects almost immediately.”130 For users seeking a
quick biochemical response, these are preferred consumption methods.
Marijuana consumed in foods or beverages, while also popular, will
produce a very different effect. The high is typically delayed—usually
appearing after 30 minutes to 2 hours—because the intestine must absorb
the drug transport it to the liver.131 Eating or drinking marijuana can also
impact dosing. Edibles “deliver[] significantly less THC into the
bloodstream than smoking [or vaping/dabbing] an equivalent amount of
the plant. Because of the delayed effects, people may inadvertently
consume more THC than they intend to.”132 According to NIDA, variable
potency rates and the delayed effect of ingestion are common causes of
overconsumption.133 The effects of marijuana will typically last a few
hours, although detectable amounts of THC can remain in the body for
days or even weeks.134 However, the choice of a particular consumption
method can alter the “duration of the psychotropic effects, the effects on
organ systems, and the addictive potential and negative consequences
associated with its use.”135
Pharmacokinetic research, which explores the absorption,
distribution, metabolism, and excretion of drugs, is a generally
complicated field.136 Confounding factors specific to marijuana research
include: (1) problems created by low concentrations of relevant chemical
constituents; (2) the rapid and extensive metabolism of THC in the body;
and (3) the complexity of separating different compounds of interest from
other compounds and biological tissues.137 Research into the specific
128. Id.
129. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 51.
130. NIDA, MARIJUANA, supra note 48, at 8.
131. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 51.
132. NIDA, MARIJUANA, supra note 48, at 8; see also Bridgeman et al., supra note 51,
at 182.
133. NIDA, MARIJUANA, supra note 48, at 8.
134. Id.
135. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 51.
136. See generally Marilyn A. Huestis, Human Cannabinoid Pharmacokinetics, 4
CHEMISTRY & BIODIVERSITY 1770 (2007) (illustrating the complexity of cannabinoid
pharmacokinetics).
137. See Bridgeman et al., supra note 50, at 182.
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pharmacokinetics of marijuana is further complicated by the many
different available methods of consumption.138 For example, we know that
the “[i]nhaled THC causes a maximum plasma concentration within
minutes, psychotropic effects start within seconds to a few minutes, reach
a maximum after 15-30 minutes, and taper off within 2-3 hours.”139 In
contrast, psychotropic effects of orally ingested marijuana manifest within
“30-90 minutes, reach their maximum after 2-3 hours and last for about 412 hours, depending on dose and specific effect.”140 The increasing array
of consumption options poses challenges to the accuracy, consistency, and
future validity of any pharmacokinetic findings.
The psychoactive effects of marijuana, which are a factor for both
medicinal and recreational users, also vary wildly based on the individual
consumer. Common reported experiences “include heightened sensory
perception (e.g., brighter colors), laughter, altered perception of time, and
increased appetite.”141 In anecdotal reports compiled by NIDA, many
people also feel “a pleasant euphoria and sense of relaxation,” although
some pot users instead report feeling “anxiety, fear, distrust, or panic.”142
There are also reports of users who “experience an acute psychosis, which
includes hallucinations, delusions, and a loss of the sense of personal
identity[,]” especially after taking larger marijuana doses.143 A recent
study published in the Journal of Child Psychology and Psychiatry
suggests the possibility that some adolescent marijuana users may
experience “psychotic-like experiences” including perceptual
abnormalities and delusional thoughts.144 However, NIDA reports that
“unpleasant but temporary reactions [to marijuana] are distinct from
longer-lasting psychotic disorders, such as schizophrenia . . . .”145
3. Marijuana Use for Creativity
Many recreational use proponents cite anecdotal evidence of
marijuana’s positive effect on creativity. For example, television
personality Bill Maher, a long-time cannabis aficionado, posits that
marijuana is linked to creativity: “[I]f I’m staring at the blank computer
screen sober, I’m thinking, ‘Uh, I don’t want to start this, it’s an
138. See THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 385–86.
139. See Franjo Grotenhermen, Pharmacokinetics and Pharmacodynamics of
Cannabinoids, 42 CLINICAL PHARMACOKINETICS 327, 327 (2003).
140. Id.
141. NIDA, MARIJUANA, supra note 48, at 8.
142. Id.
143. Id.
144. See Josiane Bourque et al., Cannabis Use and Psychotic-Like Experiences
Trajectories During Early Adolescence: the Coevolution and Potential Mediators, 58 J.
CHILD PSYCHOL. & PSYCHIATRY 1287, 1360 (2017).
145. Id.
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ASSIGNMENT!’ Then, as soon as I’m high, which takes about three
seconds, it’s, ‘Oh, this is fun! This isn’t an assignment. It’s a GAME.’”146
Discussions of marijuana’s inspirational potential are also often supported
by a list of well-known artist habitués. A quick online search suggests that
pot has been the drug of choice for a wide range famous creative people
including jazz, rock, folk, country, rap and hip-hop musicians (Louis
Armstrong, Bob Dylan, the Beatles, Bob Marley, Willie Nelson, Jerry
Garcia, Snoop Dogg, Jay-Z, Lady Gaga, and Wiz Khalifa) and various
movie stars (Woody Harrelson, Brad Pitt, and Matthew McConaughey).
The three most recent former presidents (Barack Obama,147 George W.
Bush,148 and Bill Clinton149) each admitted to (or hinted at) marijuana use,
yet the only artist,150 has never cited marijuana as source of creative
inspiration.
Recent research suggests that the link between pot and creativity
could be more than anecdotal. Dr. Alice Flaherty, a Harvard neurologist,
has explored the effects of both alcohol and marijuana on creativity.151 Her
research demonstrates that alcohol inhibits brain activity, although the
disinhibiting effects of alcohol may reduce some obstacles to creativity—
including self-criticism.152 According to Dr. Flaherty: “One of the
important aspects of creative attention is that it’s often hyper-focused in
certain ways—and yet you have to be able to pay attention to relevant
things that you’re not expecting. Marijuana seems to help that focus.”153
However, a contradictory 2017 study concluded that although cannabis
users may “appear to demonstrate enhanced creativity, these effects are an
artifact of their heightened levels of openness to experience.”154 At the

146. How Pot Helps ‘Real Time’ Host Bill Maher Hit the High Notes, PAGE SIX (Apr.
14, 2016, 2:15 PM), https://pge.sx/2RVl8XX.
147. BARACK OBAMA, DREAMS FROM MY FATHER: A STORY OF RACE AND INHERITANCE
85–86 (1995) (admitting past marijuana and cocaine use).
148. Bush
Hinted
at
Use
of
Marijuana,
BBC
NEWS,
http://news.bbc.co.uk/2/hi/americas/4282799.stm (last updated Feb. 21, 2005).
149. Gwen Ifill, The 1992 Campaign: New York; Clinton Admits Experiment With
Marijuana in 1960’s, N.Y. TIMES (Mar. 30, 1992), https://nyti.ms/2UEe9V7.
150. Eli Watkins & Jamie Gangel, George W. Bush discovers his ‘inner Rembrandt’ in
homage to veterans, CNN (Feb. 27, 2017, 4:04 PM), https://cnn.it/2Bb93Xm.
151. See Adam Wernick, Do Alcohol and Pot Really Make You More Creative? It
Depends, PUB. RADIO INT’L (Apr. 22, 2014, 4:15 PM), http://bit.ly/2GgNvOU. See
generally ALICE W. FLAHERTY, THE MIDNIGHT DISEASE: THE DRIVE TO WRITE, WRITER’S
BLOCK, AND THE CREATIVE BRAIN (2004) (discussing the neurological bases of creativity
and the use of drugs to facilitate creative work).
152. See Wernick, supra note 151.
153. Id.
154. Emily M. LaFrance & Carrie Cuttler, Inspired by Mary Jane? Mechanisms
Underlying Enhanced Creativity in Cannabis Users, 56 CONSCIOUSNESS & COGNITION 68,
68 (2017).
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moment, most of the reports linking marijuana to creativity remain
anecdotal.
4. Cannabis Connoisseurship
As recreational marijuana has become more popular, a cottage
industry of cannabis connoisseurship has developed. Since 2014, the
Denver Post has employed a full-time marijuana editor, whose popular
website (www.thecannabist.co) reviews a wide variety of cannabis strains
and accouterments.155 Distinct cannabis character (i.e., flavor, smell,
effect, duration) is attributed to the “entourage effect,” the chemical
reaction among the hundreds of chemicals including cannabinoids,
terpenes, and flavonoids.156 The cannabis industry promotes the idea that
such entourage effects translate into psychopharmacological differences.
“In the old days, you’d smoke what you could get . . . . Now, there’ll be
so much diversity in strains that you’ll be able to pick the exact high you
want.”157 Presumably, these claims also account for differences in
dispensary prices.
Unsurprisingly, there is little science to support cannabis distinction
claims. In fact, “many scientists see the whole [connoisseurship] thing as
a pipe dream. The idea that botanical marijuana creates a synergistic
chemical effect, fingerprinting the experience with ‘uplifting’ or ‘relaxing’
or ‘munchy’ notes, is highly contentious.”158 Designer pot has captured the
public imagination, with dispensaries “listing and advertising various
cannabinoid ratios and providing detailed terpene profiles in certain strains
and products.”159 Claims of psychoactive effect variations linked to
different cannabis strains or varieties, like claims of medical benefits, have
never been scientifically validated because “[d]ouble-blind clinical trials,
the gold standard for research studies in medicine, have never been
conducted to investigate the effects of marijuana’s terpenes or its
cannabinoids other than THC.”160 Even THC, as discussed in more detail
herein, has been subjected to only the most preliminary scientific testing.

155. See THE CANNABIST, https://www.thecannabist.co/ (last visited Mar. 18, 2019)
(the website’s footer notes that The Cannabist is an edition of The Denver Post).
156. Angus Chen, Some of the Parts: Is Marijuana’s “Entourage Effect” Scientifically
Valid?, SCIENTIFIC AMERICAN (Apr. 20, 2017), http://bit.ly/2zVGAoX.
157. Palmer, supra note 100 (quoting Reggie Gaudino, Vice President of Scientific
Operations at Steep Hill, a marijuana analytics company).
158. Chen, supra note 156.
159. Id.
160. Id.
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In the 30 states that have enacted medicinal marijuana statutes,
lawmakers typically specify eligible diseases and conditions. These lists
run the gamut. Alabama, one of the most restrictive states, legalized
cannabis only for use in state-sponsored clinical research trials aimed at
treating severe, debilitating epileptic conditions.161 Michigan, in contrast,
recently became one of the most permissive states when it expanded its
medical authorization to 22 different conditions including: PTSD, Cancer,
Glaucoma, HIV, AIDS, Hepatitis C, Amyotrophic Lateral Sclerosis,
Crohn’s disease, agitation of Alzheimer’s disease, Nail Patella, Autism,
chronic pain, Colitis, Inflammatory Bowel Disease, Obsessive
Compulsive Disorder, Parkinson’s, Rheumatoid Arthritis, spinal cord
injury, Tourette’s syndrome, and Ulcerative Colitis.162
In the more permissive states, a specific diagnosis may not be
required to obtain legal medical cannabis. For example, in addition to a
long list of eligible diseases and conditions, California includes a catchall
provision to accommodate:
Any other chronic or persistent medical symptom that either: (A)
Substantially limits the ability of the person to conduct one or more
major life activities as defined by the Americans with Disabilities Act
of 1990 . . . . (B) If not alleviated, may cause serious harm to the
patient’s safety or physical or mental health.163

Like California, Michigan has legalized medicinal marijuana to treat any
“chronic or debilitating disease or medical condition . . . that produces . . .
cachexia or wasting syndrome; severe and chronic pain; severe nausea;
seizures (including but not limited to those characteristic of epilepsy); or
severe and persistent muscle spasms (including but not limited to those
characteristic of multiple sclerosis or arthritis).”164 As new states expand
their qualifying conditions to include more diseases/conditions and
generalized pain and symptomology, more people will start using
marijuana, despite the fact that half-century old obstacles to researching
marijuana’s treatment or palliative efficacy will likely remain in place.

161. See UAB Cannabidiol Program, UNIV. OF ALA. BIRMINGHAM SCH. OF MED.,
http://bit.ly/2PBpEJa (last visited Mar. 18, 2019).
162. See Michigan Medical Marijuana Laws, US LEGAL, https://bit.ly/2qyrO2l (last
visited Mar. 18, 2019).
163. CAL. HEALTH & SAFETY CODE ANN. § 11362.7(12)(A)–(B) (West 2018).
164. See US LEGAL, supra note 162.
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Obstacles to Medical Research
1. Research-Grade Pot

Since the 1970 enactment of the CSA, the federal government has
strictly regulated scientific marijuana research.165 As noted above, pot’s
Schedule I status combined with NIDA regulations limiting researchers to
the University of Mississippi grown “micronized powder” cannabis, have
stymied robust scientific inquiry.166 NIDA’s research-grade marijuana “is
less potent than the pot offered at dispensaries”167 because NIDA limits
distribution to “low-THC, zero-CBD strains.”168 According to one
Colorado-based PTSD researcher, local dispensaries offer products with
THC levels as high as 30%169 and although NIDA claims to provide a
product with 13% THC levels, independent testing reveals that NIDA’s
research-grade marijuana has inconsistent THC levels, which are often
lower than 13%.170 This complicates efforts to research the effects of the
marijuana products people actually use. The NIDA marijuana “available
through the federal system do[es] not sufficiently reflect the variety of
products used by consumers, [so] research conducted using cannabis
provided by NIDA may lack external validity.”171
In addition to lower THC levels, research-grade cannabis is
chemically distinct from medical and recreational “whole-plant marijuana,
which contains hundreds of active ingredients with complicated
synergistic and inhibitory interactions.”172 NIDA marijuana also “differs
from other products offered at dispensaries.”173
For years, “there has been an effort to petition the government to
expand and improve the supply of research cannabis, as researchers and
experts complain about not only the quantity of cannabis grown for
research purposes, but also its quality and the diverse array of potency,
chemical composition (cannabinoid profiles), and vehicles of consumption

165. See Webb & Webb, supra note 56.
166. See THE HEALTH EFFECTS OF CANNABIS, supra note 33, ch. 15.
167. Marisa Taylor & Melissa Bailey, Medical Marijuana’s ‘Catch-22’: Limits on
Research Hinder Patient Relief, NAT’L PUB. RADIO (Apr. 7, 2018), https://n.pr/2HMw6uN.
168. Wells, supra note 98.
169. See Christopher Ingraham & Tauhid Chappell, Government Marijuana Looks
Nothing Like the Real Stuff. See for Yourself, WASH. POST (Mar. 13, 2017),
https://wapo.st/2RI3RB7.
170. See id.
171. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 383.
172. Ilana M. Braun et al., Study Reveals That Many Oncologists Recommend Medical
Marijuana Clinically Despite Not Feeling Sufficiently Knowledgeable to Do So, DANAFABER CANCER INST. (May 10, 2018), https://bit.ly/2qnlv1j.
173. Taylor & Bailey, supra note 167.

2019

HALF-BAKED: THE SCIENCE AND POLITICS OF LEGAL POT

429

(whole flower, vaporizers, oils, tinctures, etc.).”174 Today, “cannabis oil is
popular,” but research on oil cannot be conducted “because the NIDA
supply has not yet been trialed in humans . . . [and] the FDA will say it’s
a ‘novel molecular entity’.”175 Federal research constraints also make it
“difficult for researchers who want to look at newer delivery systems”176
including “so-called edibles that are eaten like snacks.”177
2. Bureaucratic Hurdles
Investigators seeking to conduct marijuana research also encounter
many bureaucratic and financial hurdles. Specifically, U.S. laboratories
seeking to study cannabis
must navigate a series of review processes that may involve the
National Institute on Drug Abuse (NIDA), the U.S. Food and Drug
Administration (FDA), the U.S. Drug Enforcement Administration
(DEA), institutional review boards, offices or departments in state
government, state boards of medical examiners, the researcher’s home
institution, and potential funders.178

Funding is another common research barrier because “without adequate
financial support, cannabis research will be unable to inform health care
or public health practice or to keep pace with changes in cannabis policy
and patterns of cannabis use.”179
To date, NIDA scientists have conducted the majority of cannabis
research, but federal allocation of research funds has the power to skew
the direction of inquiry. For example, in 2015 “only 16.5 percent
($10,923,472) of NIDA’s spending on cannabinoid research supported
studies investigating therapeutic properties of cannabinoids”180 with the
remaining 83.5% allocated to risk assessment research. It is possible, but
far from certain, that the current massive shift to greater legal medicinal
and recreational marijuana use could eventually provide an increased
evidence base of its effects provoking the federal government to remove
current research obstacles. A more balanced investigatory approach by
NIDA could yield a more comprehensive picture of potential health costs
and benefits. However, given our current domestic policies, some of this
new data may come from abroad.
174. John Hudak & Christine Stenglein, AG Sessions Blocks Progress on Medical
Cannabis Research, BROOKINGS INST. (Oct. 25, 2017), https://brook.gs/2S0oSYi.
175. Wells, supra note 98.
176. Id.
177. Taylor & Bailey, supra note 167.
178. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 378–79.
179. Id. at 384.
180. Id.
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3. Help from Abroad
Marijuana’s Schedule I status only limits domestic research. Because
marijuana proponents have not, and likely will not, advocate for removing
marijuana from Schedule I, we may need to rely on research conducted in
other countries to inform U.S. policymaking. For example, Canada has a
national Centre on Substance Use and Addiction [CCSUA], which “was
created by Parliament to provide national leadership to address substance
use in Canada. . . . [and] produce guidance for decision makers by
harnessing the power of research, curating knowledge and bringing
together diverse perspectives.”181
In August 2017, the CCSUA issued a National Research Agenda on
the Health Impacts of Non-Medical Cannabis Use.182 This national
research agenda “defines important areas for cannabis research and
identifies priorities for those working in the field.”183 These steps include
the following: (1) “identify[ing] current knowledge and research gaps
related to the health effects of non-medical cannabis use;” (2)
“identify[ing] existing data sources that can augment available data and
knowledge in this area;” (3) “prioritiz[ing] the short-, medium- and longterm opportunities for research on the health effects of non-medical
cannabis use;” and (4) discussing opportunities for collaboration among
researchers and tangible next steps for moving forward with the research
agenda.”184
In Spain, the Observatorio Español de Cannabis Medicinal (an
organization of cannabis scientists) sponsors an annual conference. 185
During this conference, scientific research on topics including cancer and
cannabis, pain and cannabis, and cannabis analytics were presented.186
In the future, overseas labs may provide useful scientific research,
but with marijuana consumption rates rising rapidly, U.S. researchers are
at a significant disadvantage. Over the past half century, federal
restrictions have ensured that “[c]linical research regarding the therapeutic
benefits of cannabis (“marijuana”) has been almost non-existent in the

181. About CCSA, CANADIAN CTR. ON SUBSTANCE ABUSE & ADDICTION,
http://www.ccdus.ca/Eng/About-CCSA/Pages/default.aspx (last visited Mar. 18, 2019).
182. CANADIAN CTR. ON SUBSTANCE ABUSE & ADDICTION, NATIONAL RESEARCH
AGENDA ON THE HEALTH IMPACTS OF NON-MEDICAL CANNABIS USE 1 (2017),
https://bit.ly/2Qs5X83 [hereinafter CCSA, RESEARCH AGENDA].
183. National Research Agenda on Cannabis, CANADIAN CTR. ON SUBSTANCE ABUSE
& ADDICTION, http://bit.ly/2PD0k5u (last visited Mar. 18, 2019).
184. CCSA, RESEARCH AGENDA, supra note 182, at 3.
185. See Ponencias, OBSERVATORIO ESPAÑOL DE CANNABIS MEDICINAL,
http://oedcm.com/NUEVAWEBOEDCM/ponencias-2017/ (last visited Mar. 18, 2019)
(Spain).
186. Id.
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United States.”187 As one epilepsy researcher summarized the global
problem, people can easily buy and use a huge selection of marijuana
products, but U.S. scientists cannot investigate “the safety, efficacy, and
dosing of artisanal preparations available from dispensaries . . . and online
sources.”188 This can lead to absurd results. In one laboratory “[t]he DEA
visited and determined that we had to do more to bolt down the locked
freezer,” but it was “kind of comical, with all of these medical marijuana
dispensaries scattered around town, sitting in my office and talking about
everything we had to do to get a small amount of THC, cannabidiol, and
cannabinol – 400 milligrams.”189
4. The Federal Response
NIDA is well aware of researchers’ concerns. In response to a 2016
NIDA Request for Information, scientists across the country raised the
following specific problems: (1) the lack of marijuana strains and products
reflecting the diversity of products available in state dispensaries; (2) the
lack of potency (i.e., marijuana with a higher THC content would better
represent available products); (3) the small number and variety of
marijuana chemotypes which precluded research into cannabinoids other
than THC, terpenes, and flavonoids; (4) the lack of access to common
marijuana strains (e.g., “those characterized as ‘indica’, ‘sativa’, and
‘hybrid’”); and (5) the poor quality of placebo marijuana, which “does not
smell, taste, or look like regular marijuana and thus does not serve as an
effective placebo.”190 In an apparent response issued in August 2016, the
DEA announced that it would expand its marijuana cultivation program to
allow other growers to apply.191 But in November 2016 (after the DEA
received 26 new site applications from potential pot growers), then U.S.
Attorney General Jeff Sessions reversed course.192 To date, no additional
marijuana cultivation sites have been federally approved.
187. Webb & Webb, supra note 56, at 109.
188. Brooke K. O’Connell et al., Cannabinoids in Treatment-Resistant Epilepsy: A
Review, 70 EPILEPSY & BEHAV. 341, 341 (2017); see also Chen, supra note 156 (quoting
Margaret Haney, a neurobiologist at Columbia University and cannabis researcher: “I
would love to do a study comparing strains . . . . I would love to directly compare but I’m
unable to work with any marijuana on the street or in dispensaries.”).
189. Wells, supra note 98.
190. NIDA, Summary of RFI, supra note 65.
191. See Hudak & Stenglein, supra note 174.
192. See id. (opining that this decision was based solely on personal “ideological
biases” and the Attorney General’s “absolute aversion” to all forms of marijuana, observing
that the Attorney General’s views are inconsistent with the views of President Trump, and
asking that the Attorney General “listen[] to the experts around him who understand the
needs of the medical research community,” “get[] out of the way of the free conduct of
medical research,” and “stop[] coming between patients and answers to important medical
questions.”).
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What We Know So Far
1. Recent Global Meta-Analyses
a. The National Academies of Sciences, Engineering,
and Medicine

In 2017, the National Academies of Sciences, Engineering, and
Medicine (“NASEM”) published a four hundred and sixty-eight page
report entitled: The Health Effects of Cannabis and Cannabinoids: The
Current State of Evidence and Recommendations for Research.193 The
NASEM report provides a meta-review of extant research into the health
effects and health risks of cannabis and cannabis-derived products.194 The
NASEM conducted an extensive search of literature databases “giving
primacy to recently published systematic reviews (since 2011) and highquality primary research that studied 1 or more of 11 groups of health
endpoints.”195 The health “endpoints” explored by the NASEM included a
comprehensive analysis of potential therapeutic effects for a variety of
medical and mental health diseases and conditions.196 The NASEM’s
aggregation of health endpoints reflects the research conducted to date on
marijuana’s claimed beneficial health effects.
Based on this literature review, the NASEM reached the following
conclusions about marijuana’s treatment and palliative efficacy. Cannabis
has the following potential therapeutic effects: (1) “in adults with
chemotherapy-induced nausea and vomiting, oral cannabinoids are
effective antiemetics;” (2) “[i]n adults with chronic pain, patients who
were treated with cannabis or cannabinoids are more likely to experience
a clinically significant reduction in pain symptoms;” (3) “[i]n adults with
multiple sclerosis (MS)-related spasticity, short-term use of oral
cannabinoids improves patient-reported spasticity symptoms.”197 These
studies suggest that marijuana may reduce specific symptoms currently
treated by other medication.
With respect to cancer risks, the NASEM reached the following
conclusions: (1) “smoking cannabis does not increase the risk for certain
cancers (i.e., lung, head, and neck) in adults;” (2) cannabis use may be
“associated with one subtype of testicular cancer;” and (3) “[t]here is
minimal evidence that parental cannabis use during pregnancy is
associated with greater cancer risk in offspring.”198 These studies alone
193.
194.
195.
196.
197.
198.

THE HEALTH EFFECTS OF CANNABIS, supra note 33.
See generally id.
Id. at 31.
Id.
Id. at 85.
Id. at 141.
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reveal very little about potential links between marijuana use and the full
ranges of cancer risks and nothing about the dosage-response connection
for any specific form of cancer.
The NASEM raised unequivocal concern about the impact of
cannabis use on respiratory diseases (e.g. bronchitis, asthma, emphysema,
pneumonia). With respect to respiratory diseases, there is scientific
support for the following findings: (1) “[s]moking cannabis on a regular
basis is associated with chronic cough and phlegm production;” (2)
“[q]uitting cannabis smoking is likely to reduce chronic cough and phlegm
production;” and (3) it is “unclear whether cannabis use is associated with
COPD, asthma, or worsened lung function.”199 These studies suggest that
marijuana may pose health risks to those suffering from mild respiratory
diseases, such as acute bronchitis, and to those suffering from chronic
conditions, such as emphysema and lung cancer.
The NASEM also found scientific support for the following mental
health risks and benefits: (1) “cannabis use is likely to increase the risk of
developing schizophrenia and other psychoses;” (2) “in individuals with
schizophrenia and other psychoses, a history of cannabis use may be
linked to better performance on learning and memory tasks;” (3) “cannabis
use does not appear to increase the likelihood of developing depression,
anxiety, and posttraumatic stress disorder;” (4) “heavy cannabis users are
more likely to report thoughts of suicide than nonusers;” and (5) “regular
cannabis use is likely to increase the risk for developing social anxiety
disorder.”200 Although clearly not definitive, the mental health research
suggests the possibility of various psychological risks, including the risk
of suicide, especially to users suffering from a preexisting mental health
condition.
Finally, despite the ambitious scope of the NASEM study, its
principal author candidly acknowledged that any conclusions must be
understood in the context of the current evidence void. Despite massive
increases in use, there is very little scientifically valid evidence to support
marijuana and almost nothing is known about the efficacy, dose,
administration, or side effects of commercially available marijuana
products. The current dramatic increase in legal marijuana use could
eventually provide an increased evidence base of pot’s effects that might
help convince the federal government to lift research obstacles. For now,
as principal author Dr. Donald Abrams explained, “barriers to conducting
comprehensive research . . . mean patients and providers may lack
treatment options and policymakers may lack a full evidence base

199. Id. at 181.
200. Id. at 289.
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constitute[ing] a public health problem.”201 So despite the massive new
NASEM meta-analysis, we continue to know very little about marijuana’s
claimed health benefits and even less about potential physical and mental
health risks.
b. The World Health Organization
In 2017, the World Health Organization (“WHO”) issued its own
report on the potential therapeutic uses and acute and chronic effects of
cannabis and cannabinoid use.202 With respect to the therapeutic uses of
cannabinoids, the WHO reported that “[s]everal studies have
demonstrated the therapeutic effects of cannabinoids for nausea and
vomiting in the advanced stages of illnesses such as cancer and AIDS.”203
The WHO also noted other promising therapeutic uses including
“treatment of asthma and glaucoma, as an antidepressant, appetite
stimulant, anticonvulsant and anti-spasmodic, [although] research in this
area should continue.”204 This research, like the NASEM report, suggests
that cannabis and cannabinoids may have specific health benefits for
conditions currently treated by other medications.
The WHO reported the following acute and chronic physiological
and psychological effects. The developing research into acute effects
includes evidence that: (1) “cannabis impairs cognitive development;” and
(2) that “cannabis impairs psychomotor performance in a wide variety of
tasks, such as motor coordination, divided attention, and operative tasks
of many types.”205 The WHO also reported the following chronic
physiological and psychological effects principally associated with heavy
or long-term use: (1) “selective impairment of cognitive functioning which
include the organization and integration of complex information involving
various mechanisms of attention and memory processes;” (2)
“development of a cannabis dependence syndrome characterized by a loss
of control over cannabis;” (3) “exacerbate[ion] [of] schizophrenia in
affected individuals;” (4) “epithelial injury of the trachea and major
bronchi;” (5) “airway injury, lung inflammation, and impaired pulmonary
defense against infection;” and (6) “a higher prevalence of symptoms of
chronic bronchitis and a higher incidence of acute bronchitis.”206 This
research echoes many of the findings of the NASEM report, but highlights

201.
202.
203.
204.
205.
206.

See Wells, supra note 98.
See WHO, Cannabis, supra note 63.
Id.
Id.
Id.
Id.
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more specific cognitive functioning and memory concerns and addiction
(cannabis dependency syndrome) risks.
On the specific question of fetal health, the WHO (unlike the
NASEM) reported that cannabis used during pregnancy is “associated
with impairment in fetal development leading to a reduction in birth
weight” and “may lead to postnatal risk of rare forms of cancer although
more research is needed in this area.”207 On the issue of the inadequacy of
the extant data and its impact on the preliminary nature of any conclusions,
the WHO report authors agreed with the authors of the NASEM study.
According to the WHO authors, worldwide research is insufficient and, in
particular, “the health consequences of cannabis use in developing
countries are largely unknown because of limited and non-systematic
research.”208
2. Marijuana and the Developing Brain
Most studies show that recreational marijuana use is more popular
among teenagers and younger adults.209 Growing use among younger
adults raises concerns about the potential effects of cannabis on the
developing brain. Unfortunately, as with all other areas of nascent
marijuana science, the neuroscience literature is inconclusive and
contradictory. These problems are well illustrated by the few widely cited
brain development studies.
A 2012 study found that regular cannabis use can be “associated with
neuropsychological decline broadly across domains of functioning,” that
regular users “reported noticing more cognitive problems,” and that
“impairment was concentrated among adolescent-onset cannabis users,
with more persistent use associated with greater decline.”210 CBD has no
recreational value. But like marijuana, new research suggests that CDB
may have independent therapeutic potential. For example, there is recent
“evidence that chronic pain, inflammation and insomnia are better relieved
by cannabis high in cannabidiol (CBD).”211 However, there is also
evidence that, without THC, CBD may not be as effective for some
therapeutic purposes. For example, there is research suggesting that
“[c]ancer-related nausea and poor appetite . . . are better relieved by
cannabis high in THC, the psychotropic component of marijuana.”212
Although the data is very limited, this suggests that the interaction between
207. Id.
208. Id.
209. See THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 61–63.
210. Madeline H. Meier et al., Persistent Cannabis Users Show Neuropsychological
Decline from Childhood to Midlife, 40 PROCEEDINGS NAT’L ACAD. SCI. 2657, 2657 (2012).
211. Id.
212. Wells, supra note 98.
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CBD and THC might impact therapeutic benefits and raises questions
about the general medical value of the myriad CBD-only products
currently available.
Recently, researchers began to explore the scientific therapeutic
potential of both THC and CBD on epilepsy.213 Early studies yielded
inconclusive results, but numerous scientists believe that epilepsy research
merits further targeted investigation, based in part on a long history of
anecdotal reports of reduced symptomology by epileptic cannabis users.214
More recent research suggests that CBD may be useful for epilepsy
treatment and that it may also have more generalized neuroprotective
effects.215 In a clear endorsement of the quality of science in this specific
field, in June of 2018, the FDA approved the first CBD-derived drug
(Epidiolex) for the treatment of pediatric epilepsy.216
CBD also showed early promise in the treatment of a range of
neuropsychiatric disorders. In a decade-old animal study, CBD showed
promise for the treatment of schizophrenia.217 More recently, CBD has
been shown to have potentially beneficial effects for a “range of
neurodegenerative conditions and psychiatric disorders.”218 These include
the alleviation of symptoms for patients diagnosed with schizophrenia,219
epilepsy,220 and multiple sclerosis.221 In other recent research, CBD has
been shown to have measurable anti-anxiety, antipsychotic, antiemetic and
anti-inflammatory properties.222 In a 2017 study, these promising
neuroprotective effects were linked to CBD’s demonstrated antioxidant
and anti-inflammatory activities.223 These studies suggest that CBD may
213. Orrin Devinsky et al., Cannabidiol: Pharmacology and Potential Therapeutic
Role in Epilepsy and Other Neuropsychiatric Disorders, 55 EPILEPSIA 791 (2014).
214. Carmen Mannucci et al., Neurological Aspects of Medical Use of Cannabidiol, 16
CNS & NEUROLOGICAL DISORDERS – DRUG TARGETS 541, 543 (2017).
215. Id. at 543, 551.
216. FDA Approves First Drug Comprised of an Active Ingredient Derived from
Marijuana to Treat Rare, Severe Forms of Epilepsy, FOOD & DRUG ADMIN. (June 25,
2018), https://bit.ly/2AqKHMq.
217. Raquel Levin et al., Antipsychotic Profile of Cannabidiol and Rimonabant in an
Animal Model of Emotional Context Processing in Schizophrenia, 18 CURRENT
PHARMACEUTICAL DESIGN 4960, 4961–62 (2012).
218. Alline C. Campos et al., Cannabidiol, Neuroprotection and Neuropsychiatric
Disorders, 112 PHARMACOLOGICAL RESEARCH 119, 120 (2016).
219. Levin, supra note 217, at 4963.
220. Devinsky, supra note 213, at 800.
221. Thorsten Rudroff & Jacob Sosnoff, Cannabidiol to Improve Mobility in People
with Multiple Sclerosis, FRONTIERS IN NEUROLOGY (Mar. 22, 2018),
https://doi.org/10.3389/fneur.2018.00183.
222. See Mateus Machado Bergamaschi et al., Safety and Side Effects of Cannabidiol,
a Cannabis Sativa Constituent, 6 CURRENT DRUG SAFETY 237, 237 (2011).
223. Mannucci, supra note 214, at 541; see also What’s This About P-Glycoprotein?,
TREATMENT ACTION GRP. (July 2000), http://www.treatmentactiongroup.org/tagline/
2000/july/whats-about-p-glycoprotein.

2019

HALF-BAKED: THE SCIENCE AND POLITICS OF LEGAL POT

437

have a range of medical and palliative benefits creating the possibility that
CBD might provide a non-psychoactive alternative to marijuana.
Despite the absence of THC, CBD has already been associated with
various health risks. Recent CBD studies report “side effects, including
inhibition of hepatic drug metabolism, alterations of in vitro cell viability,
decreased fertilization capacity, and decreased activities of p-glycoprotein
[a multidrug resistant protein that serves as a cell defense to harmful
substances] and other drug transporters.”224 This study suggests that CBD
may pose a risk of injury to the liver, impede fertility treatment, or interfere
with proteins that help necessary transport within the body and cell
protection from foreign substances.
In 2017, the WHO addressed comparative CBD and cannabis
addiction risks.225 According to the WHO, “cannabidiol [CBD] is not [as]
likely to be abused or create dependence as . . . other cannabinoids (such
as Tetra Hydro Cannabinol (THC), for instance).”226 Based on this finding,
the WHO concluded “[t]o date, there is no evidence of recreational use of
CBD or any public health related problems associated with the use of pure
CBD.”227 This finding may make sense, given CBD’s lack of THC, but
because CBD remains subject to identical Schedule I restrictions – as
“little is known about its safety and side effect profile in animals and
humans,”228 as is known about cannabis.
E.

Physician Quasi-Acceptance

According to a 2013 New England Journal of Medicine [NEJM] poll,
76% of doctors favor the legalization of medicinal marijuana.229 A 2018
Dana-Farber Cancer Institute study confirmed these findings within the
oncological community.230 This study, which involved a random sampling
of oncologists, noted widespread physician support and found that nearly
50% of oncologists actually recommended marijuana to their patients.231
However, the 2018 study also revealed that most doctors who
recommended marijuana also expressed concern that more and better
research is needed.232Dr. Ilana Braun, M.D., a co-author of the Dana224. Bergamaschi et al., supra note 222, at 237.
225. See generally CANNABIDIOL (CBD) PRE-REVIEW REPORT, WORLD HEALTH
ORGANIZATION [WHO] (39th Expert Committee on Drug Dependence, 2017),
https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf.
226. Id. (emphasis added).
227. Id.
228. See Bergamaschi et al., supra note 222, at 237.
229. Jonathan N. Adler & James A. Colbert, Medicinal Use of Marijuana — Polling
Results, 368 NEW ENG. J. MED. 866, 866 (2013).
230. Braun et al., supra note 172.
231. Id.
232. Id.
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Farber study, highlighted the fact that half of the “physicians would offer
clinical advice about a topic on which they do not feel knowledgeable[,]”
which demonstrates “the uncomfortable spot in which oncologists find
themselves.”233 The large number of physicians now recommending pot
helps to prove that the law is advancing much faster than the science.234
By 2018, medical marijuana was a legal cancer treatment in 30 states, yet
according to Dr. Braun, even marijuana proponents are aware that “the
scientific evidence base supporting use of medical marijuana in oncology
remains thin.”235
Despite survey evidence indicating growing physician support, in
practice, many doctors remain reluctant to prescribe or recommend
cannabis—even in the 30 states where medical marijuana is legal.236
Recently, Dr. Orrin Devinsky, director of New York University’s
Comprehensive Epilepsy Center and a prominent cannabidiol researcher,
described current practice tensions as linked to marijuana’s bizarre legal
status: “We have the federal government and the state governments
driving a hundred miles an hour in the opposite direction when they should
be coming together to obtain more scientific data.”237 To the extent that
Dr. Devinsky is accurately characterizing physician opinion, the ongoing
Schedule I status of cannabis and CBD remains a big impediment for
mainstream medical acceptance.
Patients may also contribute to acceptance problems and to poor
communication with their physicians. According to Dr. Peter Grinspoon
of Massachusetts General Hospital: “Many patients find themselves in the
situation of wanting to learn more about medical marijuana, but feel
embarrassed to bring this up with their doctor. . . . Other patients are
already using medical marijuana, but don’t know how to tell their doctors
about this for fear of being chided or criticized.”238 To solve or alleviate
these problems, Dr. Grinspoon offers the following suggestions: “My
advice for doctors is that whether you are pro, neutral, or against medical
marijuana, patients are embracing it, and although we don’t have rigorous
studies and ‘gold standard’ proof of the benefits and risks of medical
marijuana, we need to learn about it, be open-minded, and above all, be
non-judgmental.”239 The advice that it is better for patients and physicians
to speak candidly with each other is always true, although Dr. Grinsppon

233. Id.
234. Id.
235. Id.
236. Taylor & Bailey, supra note 167.
237. Id.
238. Peter Grinspoon, Medical Marijuana, HARV. MED. SCH. (Jan. 15, 2018, 10:30
AM), https://bit.ly/2nGkT67.
239. Id.
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may be correct that marijuana’s ongoing federal illegality raises specific
concerns in the mind of both.
IV.

THE LAW OF POT

A.

Federal-State Preemption

If we begin at the beginning, Article VI of the U.S. Constitution
provides that “the laws of the United States . . . shall be the supreme law
of the land; . . . any Thing in the Constitution or Laws of any state to the
Contrary notwithstanding.”240 In the two centuries since 1819, when
M’Culloch v. Maryland241 was decided, the Supremacy Clause has
consistently been understood to mean that any state law found to conflict
with a federal law governing the same activity is without effect.242 More
recently, the Supreme Court reified the state sovereignty debate by finding
that Supremacy Clause questions must “start with the assumption that the
historic police powers of the States [are] not to be superseded by [any]
Federal Act unless that [is] the clear and manifest purpose of Congress.”243
Regardless of whether federal law or state law emerges triumphant, in all
preemption analyses a determination of Congressional purpose must be
the “ultimate touchstone.”244
Congressional intent may be the “touchstone” of preemption, but
legislative purpose is not always readily apparent. In practice, preemption
questions typically arise under two distinct circumstances. Relatively
simple cases arise “[w]hen Congress legalizes a private activity that has
been banned by the states, [making] the application of the Supremacy
Clause . . . relatively straightforward.”245 Harder cases, like the marijuana
example, arise “[w]hen Congress bans some activity that has been
legalized by the states, . . . [because] both the legal status and practical
import of state law are far less obvious.”246 Preemption questions can arise
in the full range of criminal and civil contexts where federal and state
jurisdiction overlaps including public health and safety, civil rights
protections, and products liability. To help accommodate these different
problems of statutory conflicts, the Supreme Court has delineated three
types of federal-state preemption: (1) express (2) (implied) field, and (3)
(implied) conflict.

240.
241.
242.
243.
244.
245.
246.

U.S. CONST. art. VI, cl. 2.
M’Culloch v. Maryland, 17 U.S. 316 (1819).
Id. at 427.
Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947).
Retail Clerks Int’l Ass’n Local 1625 v. Schermerhorn, 375 U.S. 96, 103 (1963).
Mikos, supra note 16, at 1422.
Id.
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Easier cases typically involve express preemption. In these cases, a
reviewing court must simply pinpoint the explicit congressional
command.247 This will normally involve a specific judicial finding that
Congress “declare[d] in express terms its intention to preclude local action
in a given area.”248 In harder cases where there is no express congressional
intent, field preemption can be implied. This will normally involve a
finding that a state is “precluded from regulating conduct in a field that
Congress has determined must be regulated by its exclusive
governance.”249 However, field preemption requires a reviewing court to
find a framework of federal regulation “so pervasive . . . that Congress left
no room [in the field] for the States to supplement it”250 or a “federal
interest . . . so dominant that the federal system will be assumed to
preclude enforcement of state laws on the same subject.”251 Finally, and
equally challenging, conflict preemption may only be implied when
“compliance with both federal and state regulations is a physical
impossibility”252 or if the challenged state law “stands as an obstacle to the
accomplishment and execution of the full purposes and objectives of
Congress.”253 Cases sometimes involve both implied field and implied
conflict preemption. Under these circumstances, the Court has cautioned,
even without evidence of a clear expression of legislative intent,
preemption must still be “the clear and manifest [implied] purpose of
Congress.”254
As more states legalize medicinal and recreational pot, the potential
preemptive effect of the CSA has been a subject of growing academic
attention. Professor Erwin Chemerinsky has opined that “marijuana
regulation is one of the most important federalism conflicts in a
generation.”255 In his view, the conflict between federal criminalization
under the CSA and state legalization “raises questions of tension and
cooperation between state and federal governments[,] . . . forces
policymakers and courts to address the preemptive power of federal drug
laws. . . . [and] create debilitating instability and uncertainty on the ground
in those states that are pioneering new approaches to marijuana control.”256
247. Id.
248. S.C. State Ports Auth. v. Jasper Cty., 629 S.E.2d 624, 628 (S.C. 2006).
249. Arizona v. United States, 567 U.S. 387, 399 (2012).
250. Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947).
251. Id.
252. Fla. Lime & Avocado Growers v. Paul, 373 U.S. 132, 142–43 (1963).
253. Arizona, 567 U.S. at 399.
254. Rice, 331 U.S. at 230.
255. Chemerinsky et al., supra note 85, at 76.
256. Id. The federalism problems created by state legalization of marijuana are legion.
Federally insured banks may decline to accept money from marijuana commerce
because of the threat of money laundering prosecutions, leaving the businesses
largely cash-only and cash-on-site. Marijuana dispensaries may not deduct
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Other scholars disagree that marijuana’s simultaneous illegality and
legality is destabilizing. For example, Professor Ira Robbins recently
argued that “conflicting federal and state marijuana laws can coexist”
because “federalism allows states ‘great latitude under their police powers
to legislate as to the protection of the lives, limbs, health, comfort, and
quiet of all persons.’”257 In Professor Robbins view, the theoretical tension
has no practical import, because, in effect, “[a]ffording states broad
authority promotes innovation and the potential for states to serve as
smaller experimental vehicles for new ideas.”258 Tension, in Professor
Robbin’s view, is not just unproblematic, it has social value.
To date, many of the marijuana legalization preemption questions
have arisen in the context of employment law and the construction of the
Americans with Disabilities Act (“ADA”). In these cases, federal courts
typically find implied preemption because they
commonly hold that state marijuana laws are preempted by the CSA,
that an employee’s use of marijuana is not protected under the ADA,
and that an employers’ zero-tolerance (or similar) drug policy is an
acceptable basis upon which to terminate a medical marijuana user’s
employment, rescind a job offer, or refuse to hire a candidate.259

To date, the Supreme Court has not addressed the preemptive effect of the
CSA.260 If the federal decisions become more divided, this would create
greater impetus for Supreme Court review.
The text of the CSA, which is fundamental to any preemption
determination, reads as follows:
No provision of this subchapter shall be construed as indicating an
intent on the part of the Congress to occupy the field in which that
provision operates, including criminal penalties, to the exclusion of
any State law on the same subject matter which would otherwise be

business expenses from federal taxes. Lawyers may encounter ethical dilemmas
advising marijuana businesses because attorneys cannot knowingly assist clients
in illegal conduct, even if that conduct is legal in state in which the lawyer
practices or the client acts.
Jessica Berch, Reefer Madness: How Non-Legalizing Slates Can Revamp Dram Shop Laws
to Protect Themselves from Marijuana Spillover from Their Legalizing Neighbors, 58 B.C.
L. REV. 863, 970 (2017).
257. Ira P. Robbins, Guns N’ Ganja: How Federalism Criminalizes the Lawful Use of
Marijuana, 51 U.C. DAVIS L. REV. 1783, 1817 n.137 (2018) (quoting Gonzales v. Oregon,
546 U.S. 243, 270 (2006)).
258. Id.
259. Sara E. Payne & Geoffrey A. Mort, Medical Marijuana in the Workplace, N.Y.
ST. BAR ASS’N J. (July 2018), https://www.nysba.org/Journal/2018/Jul/Medical_
Marijuana_in_the_Workplace/.
260. Id. at 1442 (“The Supreme Court has never squarely addressed the [CSA]
preemption issue, despite many claims to the contrary . . . .”).
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within the authority of the State, unless there is a positive conflict
between that provision of this subchapter and that State law so that the
two cannot consistently stand together.261

It is important to note that this statutory language omits both: (1) an
express Congressional command; and (2) any text supporting an argument
that Congress expressly manifested the intent to occupy the field. In fact,
Congress clearly expressed its intent not to occupy that field.
This clear statutory language eliminates any plausible argument that
the CSA creates express or implied field preemption, leaving open only
the possibility of implied conflict preemption. At least one scholar has
explained this congressional approach and its effect as follows:
Arguably, . . . the preemptive effect of the CSA is not as broad as
congressional authority could have allowed. States remain free to pass
laws relating to marijuana, or other controlled substances, so long as
they do not create a “positive conflict” with federal law. In interpreting
this provision, courts have generally established that a state medical
marijuana law is in “positive conflict” with the CSA if it is “physically
impossible” to comply with both the state and federal law, or where
the state law “stands as an obstacle to the accomplishment and
execution of the full purposes and objectives of Congress.262

Thus, the only preemption question is whether, in jurisdictions where
marijuana is now legal, it is physically impossible to comply with both
state and federal law.
Using conflict preemption principles and general rules of statutory
construction, Congress clearly intended only to “preempt any state law that
positively conflicts with the CSA.”263 Future courts will need to decide
whether state laws legalizing marijuana for medical and recreational use
“create an impermissible ‘conflict’—as that term has been defined by the
Supreme Court—with the CSA provisions prohibiting marijuana
altogether.”264 Unsurprising, the Justices do not always agree about what
is, and what is not, impossible.
The specific question of implied conflict preemption in the context
of marijuana laws has recently attracted the attention of a various legal
authors. Professor Sam Kamin is not especially worried about preemption
challenges to state law because in his view “federal law clearly permits
states to draft their own marijuana regulations, even if those regulations
261. 21 U.S.C. § 903 (2012 & Supp. 2017).
262. TODD GARVEY, CONG. RESEARCH SERV. R42398, MEDICAL MARIJUANA: THE
SUPREMACY CLAUSE, FEDERALISM, AND THE INTERPLAY BETWEEN STATE AND FEDERAL
LAWS 9 (2012).
263. Mikos, supra note 16, at 1451.
264. Chemerinsky et al., supra note 84, at 102.
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fail to mirror the federal prohibition; the CSA explicitly disclaims any
intention to occupy the field and preempt all inconsistent state laws.”265
According to Professor Kamin, his analysis refutes the argument that
serious federal criminal marijuana penalties preempt lighter (or nonexistent) state law penalties for the same actions.266 In essence, Professor
Kamin posits that a positive conflict is required (between state and federal
law) and opines that a positive conflict does not arise when states simply
liberalize or lift marijuana penalties, and would arise only in the
implausible event that “the state were to require that which the federal
government forbids that compliance with both state and federal law would
become impossible.”267 Similarly, as Franklin Guenthner, astutely
observed in his recent law review comment, the CSA cannot preempt
“state laws that simply legalize the use of marijuana.”268 Legalization
alone does not inevitably create a positive conflict because state officers
would not be responsible for enforcing federal law.269 Under this view, to
avoid preemption problems a state must simply avoid drafting “state laws
that attempt to promote the sale, distribution, or consumption of
marijuana.”270
Unsurprisingly, state statutes legalizing marijuana do not include
language promoting marijuana sale or use. This suggests a deliberate
legislative effort to avoid “conflict[ing] directly with the proscriptions
of . . . the CSA and thus becom[ing] an obstacle to its enforcement.”271
Abjuring promotional language also precludes the possibility of creating
additional complication in the event of a federal prosecution for aiding and
abetting a federal crime.272 More generally, it is one thing to establish that
marijuana use is legal in your state and quite another to make it
recommended.
Unresolved preemption questions are principally of interest to law
professors. Without clear guidance from the Supreme Court, Professor
Erwin Chemerinsky has offered a possible resolution in the form of a new
theory of “cooperative federalism.”273 Cooperative federalism would not
depend on finding an agreed-upon definition of a positive conflict, but
265. Sam Kamin, Legal Cannabis in the U.S.: Not Whether but How?, 50 U.C. DAVIS
L. REV. 617, 624 (2018).
266. Id.
267. Id.
268. Franklin Guenthner, Pot, Printz, and Preemption: Why States Can “Just Say No”
to Jeff Sessions and the Controlled Substances Act, MINN. L. REV. DE NOVO (Apr. 26,
2017), http://bit.ly/2zY1xPO.
269. Id.
270. Id.; see also 21 U.S.C. § 856 (2012 & Supp. 2017); 18 U.S.C. § 2 (2012 & Supp.
2017).
271. Guenthner, supra note 268.
272. See 18 U.S.C. § 2.
273. Chemerinsky et al., supra note 84, at 78.
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would instead simply allow states seeking legalization to “opt out” of CSA
marijuana provisions, assuming the states could meet specific eligibility
criteria established by Congress or the DOJ.274 While Professor
Chemerinsky appears to have devised an elegant solution, it is impossible
to accurately predict the political traction or practical feasibility of his
approach.
B.

The Supreme Court Weighs In
1. Approving Federal Enforcement of the CSA

Over the past two decades, the Supreme Court has twice addressed
the specific question of federal enforcement of the CSA. United States v.
Oakland Cannabis Buyers’ Cooperative,275 decided in 2001, involved a
federal enforcement action under the CSA against Jeffrey Jones and the
nonprofit Oakland Cannabis Buyers’ Cooperative [OCBC] seeking to
enjoin them from growing and distributing marijuana under California’s
Proposition 215.276 When Mr. Jones and the OCBC openly violated the
injunction, the government initiated contempt proceedings and the
defendants argued that the distributions of marijuana were “medically
necessary.”277
The federal injunction had been granted by the district court; but
when the case reached the Ninth Circuit, the court found the medical
necessity defense legally cognizable.278 The appellate court reasoned that
because the district court had “‘broad equitable discretion’ to fashion
injunctive relief, that court could have, and should have, weighed the
‘public interest’ and considered factors such as the serious harm in
depriving patients of marijuana.”279 On remand, the district court modified
the injunction to include a medical necessity defense.280 Ultimately, the
Supreme Court would disagree with the Ninth Circuit on a variety of
grounds.
According to Justice Thomas, who wrote for the Oakland Cannabis
Buyers’ Cooperative majority, the question of a federal court’s general
authority to recognize a necessity defense (when such a defense is not
specified by statute) has never been resolved.281 However, the Court did
274. Id.
275. United States v. Oakland Cannabis Buyers’ Cooperative, 532 U.S. 483 (2001).
276. Id. at 486–87.
277. Id.
278. United States v. Oakland Cannabis Buyers’ Coop., 190 F.3d 1109, 1114 (9th Cir.
1999), rev’d, 532 U.S. 483 (2001).
279. Oakland Cannabis, 532 U.S. at 488 (citing Oakland Cannabis, 190 F.3d at 1114).
280. Id. at 488–89.
281. Id. at 490.

2019

HALF-BAKED: THE SCIENCE AND POLITICS OF LEGAL POT

445

not need to reach the broader jurisdictions issue to reject the specific
medical necessity argument advanced in this case.282 Justice Thomas
explained the Court’s reasoning as follows:
Under any conception of legal necessity, one principle is clear: The
defense cannot succeed when the legislature itself has made a
“determination of values.” In the case of the Controlled Substances
Act, the statute reflects a determination that marijuana has no medical
benefits worthy of an exception (outside the confines of a Governmentapproved research project). Whereas some other drugs can be
dispensed and prescribed for medical use, [citation omitted] the same
is not true for marijuana. Indeed, for purposes of the Controlled
Substances Act, marijuana has “no currently accepted medical use” at
all.283

Thus, in a case that arguably should have been about the science of
marijuana, the Court relied on a three-decade old congressional finding
(lacking any scientific support) to defeat a medical necessity claim
(without considering any possible supporting scientific evidence).
In addition to illustrating the Court’s disinclination to examine the
scientific evidence, Oakland Cannabis Buyers’ Cooperative also
demonstrates the bizarre circular reasoning facilitated by marijuana’s
simultaneous federal illegality and state legality. Here is the tautology: the
“Attorney General can include a drug in schedule I only if the drug ‘has
no currently accepted medical use in treatment in the United States,’”
therefore the Court must find that the drug has no medical use (making
medical necessity impossible) because the Attorney General put the drug
into Schedule I.284 The defects in this reasoning should be obvious. First,
science had advanced by three decades since the CSA was enacted, so any
medical conclusions from 1970 should be reevaluated. Second, as a matter
of logic, this is akin to arguing that insulin, if placed on Schedule I, would
cease to regulate diabetes. The Court’s rote determination that cannabis
has no potential medical purpose—because Congress said so three decades
ago—is highly problematic as a matter of science, but as a matter of law
it allowed the Court to evade the question of “medical necessity” and
precluded the introduction of any new evidence to support the argument
that marijuana has medical or palliative value.
Four years later, in Gonzales v. Raich,285 the Supreme Court upheld
enforcement of the CSA against California medical marijuana producers
on different grounds—as a proper exercise of Congressional Commerce
282.
283.
284.
285.

Id. at 491.
Id. at 491.
Id. at 492.
Gonzales v. Raich, 545 U.S. 1 (2005).
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Clause power.286 Like Oakland Cannabis Buyers’ Cooperative, Raich
arose after state and federal law enforcement officers had raided plaintiffs’
home and DEA agents had seized and destroyed plaintiffs’ marijuana
plants because they were grown in violation of the CSA.287 The Raich
Court specifically rejected the plaintiffs’ argument that the seized
marijuana was being used solely “for personal medical purposes on the
advice of a physician;” ruling instead that Congress has the authority to
designate marijuana “as contraband for any purpose.”288
On the question of medicinal use, the Court again avoided the
scientific merits and simply echoed the circular reasoning of Oakland
Cannabis Buyers’ Cooperative, holding that such use was impossible
because “Congress expressly found that the drug has no acceptable
medical uses.”289 As with the earlier case, the judicial determination that
cannabis has no possible medical use because Congress said so almost four
decades earlier, made any plaintiffs’ evidence of marijuana’s therapeutic
value irrelevant to the determination.
The Raich Court’s Commerce Clause analysis was as problematic as
its evaluation of the evidence. The seized marijuana had been grown, sold,
and used solely in California.290 All of the materials necessary for its
cultivation had also been carefully purchased within the state. Based on
these facts, the plaintiffs argued that the CSA’s “categorical prohibition,”
as applied here to the wholly “intrastate manufacture and possession of
marijuana for medical purposes,” exceeded Congress’s authority to
regulate interstate commerce.291
The Raich Court began its analysis by reviewing the three modern
forms of Commerce Clause authority:
First, Congress can regulate the channels of interstate commerce.
Second, Congress has authority to regulate and protect the
instrumentalities of interstate commerce, and persons or things in
interstate commerce. Third, Congress has the power to regulate
activities that substantially affect interstate commerce [citations
omitted].292

286. Id. at 28 (“[T]he mere fact that marijuana—like virtually every other controlled
substance regulated by the CSA—is used for medicinal purposes cannot possibly serve to
distinguish it from the core activities regulated by the CSA.”).
287. Id. at 7.
288. Id. at 26–27.
289. Id. at 27.
290. Id. at 15.
291. Id.
292. Id. at 16.
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The Court quickly concluded that only the third “substantial effect”
category could be implicated by plaintiffs’ actions.293 Thus, the question
for the Court was whether Congress has the “power to regulate purely local
activities that are part of an economic class of activities that have a
substantial effect on interstate commerce.”294
Quoting Wickard v. Filburn,295 the Raich Court observed that “even
if appellee’s activity be local and though it may not be regarded as
commerce, it may still, whatever its nature, be reached by Congress if it
exerts a substantial economic effect on interstate commerce.”296 Ignoring
both the real-world and analytic distinctions between the congressional
regulation of national wheat prices, at issue in Wickard, and the intrastate
cultivation and home use of small amounts of marijuana for personal
medicinal purposes, the Court found that the inevitable diversion of
marijuana into the national market would affect interstate commerce.297
The Raich decision seemed to ignore the basic facts and to rest, at least
partly, on the Court’s use of a four-decade-old Webster’s dictionary
definition of “economic” that included the “production of goods.”298 More
notably, the Court simply ignored the critical requirement of proof of a
“substantial” economic impact.299 Justice Scalia, who wrote for the
majority, made no effort to quantify the economic impact of the activities
at issue simply said “[w]e have never required Congress to legislate with
scientific exactitude.”300 Raich suggests that the Court will effectively
presume, despite all apparent evidence to the contrary, that certain
activities will have some effect on interstate commerce.
2. Critique of the Modern Approach to Commerce Clause
Authority
The Raich decision has been soundly criticized as an unconstitutional
expansion of Commerce Clause authority. It has also been specifically
cited as evidence of the Rehnquist Court’s federalism inconsistency and

293. Id. at 17.
294. Id.
295. Wickard v. Filburn, 317 U.S. 111 (1942).
296. Raich, 545 U.S. at 17 (quoting Wickard, 317 U.S. at 125).
297. Id. at 19 (noting that the inevitable “diversion of homegrown marijuana” would
“frustrate the federal interest in eliminating commercial transactions in the interstate
market in their entirety”).
298. Id. at 25.
299. See U.S. v. Lopez, 514 U.S. 549, 559 (finding that under the Commerce Clause,
“the proper test requires an analysis of whether the regulated activity ‘substantially affects’
interstate commerce.”).
300. Id. at 17.
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of the Court’s growing politicization.
Despite its billing as the protector of states’ rights, the [Raich] Court
gave almost as expansive an account of federal power under the
Commerce Clause as could be imagined. In order to sustain the
claimed federal interest, the Court had to find that, as applied, the CSA
was a valid exercise of the federal legislative power, notwithstanding
the lack of engagement of the home-grown marijuana with any
economic markets, intrastate or interstate.301

Writing in dissent in Raich, Justice O’Connor, argued that the decision had
improperly expanded federal powers to intrude into intrastate concerns
and to the detriment of other governmental interests. In her opinion, one
of federalism’s “chief virtues” is the promotion of innovation.302
Innovation occurs because “a single courageous State may, if its citizens
choose, serve as a laboratory; and try novel social and economic
experiments without risk to the rest of the country.”303 According to Justice
O’Connor, Raich exemplified the virtue of state innovation, but the Court
had applied the CSA to “extinguish[] that experiment, without any proof
that the personal cultivation, possession, and use of marijuana for
medicinal purposes, if economic activity in the first place, has a substantial
effect on interstate commerce and is therefore an appropriate subject of
federal regulation.304 Raich was also a complete departure from the
fundamental federalism principles articulated in just ten years earlier in
United States v. Lopez.305
A similar critique has been advanced by various legal scholars.
Shortly after Raich was decided, Professor Thomas Merrill opined that the
decision signaled the Court’s “ill-advised” federalism shift away from
clear rules and towards prohibitory limitations.306 In 1955, in United States
v. Lopez,307 the Court had upheld a federal “Gun-Free School Zones Act,”
based on a finding that the possession of a gun in school has no impact on
interstate commerce.308 According to Professor Merrill, Justice
O’Connor’s discussion of Lopez was intended to serve as a reminder that
Congressional ability to regulate intrastate commerce is strictly limited to
those activities that have a “substantial effect on interstate commerce [and]
301. Samuel Issacharoff & Catherine M. Sharkey, Backdoor Federalization, 53 UCLA
L. REV. 1353, 1362 (2006).
302. Raich, 545 U.S. at 42 (O’Connor, J., dissenting).
303. Id.
304. Id. at 43.
305. United States v. Lopez, 514 U.S. 549 (1995).
306. Thomas W. Merrill, Rescuing Federalism After Raich: The Case for Clear
Statement Rules, 9 LEWIS & CLARK L. REV. 823, 826 (2005)
307. United States v. Lopez, 514 U.S. 549 (1995).
308. Id. at 567.
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only if that activity is ‘economic’ in nature.”309 In Professor Merrill’s
opinion, in Raich makes it “difficult to see how growing and consuming
marijuana at home for medicinal purposes is ‘economic’ activity,” which
should have placed it “beyond the power of Congress to regulate under
Lopez.”310 But in his view, after Raich, “Lopez’s prohibitory rule was
watered down to the point where it may have little continuing
significance.”311 Both Justice O’Connor and Professor Merrill would
apparently agree that the same Commerce Clause powers the Court strictly
when a state sought to ban gun possession in school was inexplicably
expanded when an individual sought, in accordance with state law, to grow
and use medical marijuana in his home.
Since Raich, the Supreme Court has avoided the marijuana debate.
Most notably, in 2016, the Court declined by a vote of 6-2 (with Justices
Thomas and Alito dissenting), a challenge by Nebraska and Oklahoma to
Colorado’s recreational use law.312 Nebraska and Oklahoma had alleged
that the new Colorado law violated federal drug laws and “increased
trafficking and transportation of Colorado-sourced marijuana into their
territories, requiring them to expend significant law enforcement, judicial
system, and penal system resource to combat the increased trafficking and
transportation of marijuana.”313
The Court’s 2016 decision declining to hear Nebraska v. Colorado314
was viewed as a victory by marijuana legalization proponents. According
to Tom Angell, chairman of Marijuana Majority, “[t]here’s no question
about it: This is good news for legalization supporters. This case, if it went
forward and the Court ruled the wrong way, had the potential to roll back
many of the gains our movement has achieved to date.”315
C.

The Tenth Amendment
1. The Anti-Commandeering Doctrine

The Tenth Amendment provides that the “powers not delegated to the
United States by the Constitution, nor prohibited by it to the States, are
reserved to the States respectively, or to the people.”316 In Raich, the Court
clarified that the Commerce Clause provides Congress with the authority
309. Merrill, supra note 306, at 826.
310. Id.
311. Id.
312. John Ingold, Supreme Court denies Oklahoma and Nebraska challenge to
Colorado pot, DENVER POST (Mar. 21, 2016, 2:34 AM), https://dpo.st/2Lh1kf3.
313. Nebraska v. Colorado, 136 S. Ct. 1034, 1036 (Thomas, J., dissenting).
314. Id.
315. Ingold, supra note 312.
316. U.S. CONST. amend. X.
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to regulate marijuana. Although the Raich Court’s Commerce Claus
decision was clear with respect to the Congressional authority question,
any effort at federal enforcement of the CSA raises independent and
complicated Tenth Amendment concerns.
Federal enforcement of the CSA against the states would implicate
the Tenth Amendment’s “anti-commandeering doctrine.” The anticommandeering doctrine bars the federal government from forcing states
to enact laws or forcing states to assist the federal government in enforcing
federal law within a state.317 The “anti-commandeering” doctrine, as
described by the Court in 1997 in Printz v. United States,318 bars Congress
from imposing duties on state or local government officials including law
enforcement. In Printz, another case involving gun control legislation, the
Court refused to require state and local officials to comply with federal
legislation requiring background checks on prospective handgun
buyers.319 With Printz a notable exception, the anti-commandeering
doctrine has traditionally been of little practical import. Congress has
rarely attempted to commandeer state officials, and the Court has rarely
relied on this doctrine to strike down a federal statute.320
The anti-commandeering doctrine could play a greater future role in
cases where state and federal marijuana laws conflict. This doctrine, which
supports a strict divide between federal and state control, could help
impede any future CSA enforcement efforts “because it essentially tells
the federal government that it is on its own when it comes to enforcing its
own drug laws.” 321 While the federal government might continue to
successfully argue that marijuana is illegal under the CSA, its illegal status
may be of little practical import, because “state and local officials cannot
be forced to arrest or charge anyone with a violation of the CSA.”322 In
effect, the anti-commandeering doctrine makes it very unlikely that, in
states where marijuana is now legal, state law enforcement would ever
play a role in enforcing federal law.
In a very interesting new article, Professor Sam Kamim speculated
that the Court’s May 2018 anti-commandeering decision in Murphy v.
NCAA,323 striking down a federal law that had prohibited states from
legalizing sports gambling, has significant implications for the future of
marijuana legalization.324 According to Professor Kamin, the Murphy
317. See Printz v. United States, 521 U.S. 898, 912 (1997).
318. Printz v. United States, 521 U.S. 898 (1997).
319. See id. at 912.
320. Andrew B. Coan, Commandeering, Coercion, and the Deep Structure of American
Federalism, 95 B.U. L. REV. 1, 8–9 (2015).
321. Guenthner, supra note 268.
322. Id.
323. Murphy v. Nat’l College Athletics Ass’n, 138 S. Ct. 1461 (2018).
324. Id. at 1484–85.
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decision portends that “the federal government cannot prohibit states from
implementing marijuana law reform. Just as it cannot force the states to
enforce the federal marijuana prohibition, it cannot require them to keep
their own prohibitions in place, or force states that have regulated and
taxed marijuana to undo such laws.”325 If Professor Kamin is correct that
Murphy has paved the way for states to make individualized marijuana
decisions, this would be welcome news for legalization proponents.
Of course, the anti-commandeering doctrine does not prevent the
federal government from using federal law enforcement officers to enforce
the CSA. Although the Constitution cannot prevent federal law
enforcement, robust enforcement is highly unlikely because it would be
impracticable. As more states “implement laissez-faire statutes toward
marijuana consumption and distribution, the Justice Department will have
to allocate more of its own resources toward the investigation, prosecution,
and imprisonment of the hundreds of thousands of marijuana offenders
arrested and charged each year.”326 This scenario is improbable because
the “federal government lacks the resources needed to enforce its own ban
vigorously: although it commands a $2 trillion dollar (plus) budget.”327 In
practice, “the federal government is only a two-bit player when it comes
to marijuana enforcement. . . . [with] [o]nly 1 percent of the roughly
800,000 marijuana cases generated every year . . . handled by federal
authorities.”328 Given the economic realities, the largest impediment to
federal enforcement of the CSA is not deference to the states or a change
of heart about criminality, but federal inability to manage massive
additional policing costs.
2. Congressional Spending Power
Congress also has spending power (i.e., the power of the purse),
which it can use to steer the enforcement of federal law by state law
enforcement. In effect, Congress has the inherent power to shape state
public policy “by enacting spending legislation aimed at inducing states to
adopt certain approaches to public health problems.”329 However,
congressional spending power has well-established limits.
National Federation of Independent Business v. Sebelius,330 the 2012
landmark case upholding the constitutionality of the Patient Protection and
325. Sam Kamin, Murphy v. NCAA: It’s About Much More Than Gambling on Sports,
THE HILL (May 15, 2018, 8:00 AM), http://bit.ly/2SLdZth.
326. Guenthner, supra note 268.
327. Mikos, supra note 16, at 1424 (2009).
328. Id.
329. Sara Rosenbaum, Gonzales v. Raich: Implications for Public Health Policy, 120
PUB. HEALTH REPS. 680, 682 (2005).
330. Nat’l Fed’n of Indep. Bus. v. Sebelius, 567 U.S. 519 (2012).

452

PENN STATE LAW REVIEW

Vol. 123:2

Affordable Care Act (ACA or “Obamacare”), would likely govern any
future congressional spending power inquiry. In relevant part, the
Supreme Court held that the Congress could not compel states to expand
Medicaid by threatening to withhold funding for existing state Medicaid
programs.331 The Court reasoned that this exercise of federal spending
power would violate constitutional separation of powers.332 According to
the Court, Spending Clause legislation cannot be used to undermine the
sovereign power of the individual states.333 Although Sebelius provides a
recent unequivocal delineation of spending power limits, the case rests on
earlier spending power cases, in which the Court held that the separation
of powers previous decisions holding that Congress cannot use its
spending power authority to demand that states “govern according to
Congress’ instructions.”334
In sum, although Congress could try to use its spending authority to
restrict funds to state that fail to recriminalize marijuana, this strategy
might be unconstitutional. The Sebelius Court recently held that
Congress’s coercive use of its conditional spending power raises
constitutional concerns similar to those implicated under the Tenth
Amendment anti-commandeering doctrine.335 As Professor Mikos
predicted, conditional federal spending would likely be viewed as a
congressional effort to “sidestep jurisprudential limits on its authority and
accomplish otherwise impermissible objectives.”336 Conditional spending
power is viewed with skepticism as one of “federalism’s Trojan
Horses.”337 The risk, in the marijuana context, is that any Congressional
effort to incentivize the recriminalization of marijuana would be an effort
to supplant the legislative authority and judgment of duly elected state
officials and voters.
V.

CONCLUSION: POT’S UNCERTAIN POLITICAL FUTURE

A.

Recent Executive Branch Shifts

Although the status of marijuana as a Schedule I drug has been
constant for the past half-century, the modern history of federal

331.
332.
333.
334.
335.
336.
337.

Id. at 585.
Id. at 588.
Id.
New York v. United States, 505 U.S. 144, 162 (1992).
Nat’l Fed’n of Indep. Bus. v. Sebelius, 567 U.S. 519, 588 (2012).
Mikos, supra note 16, at 1461.
Id.
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enforcement policy has been wildly inconsistent.
The United States Justice Department under the Clinton
Administration took the position that the CSA did not apply to
Schedule I drugs such as marijuana in states with medical use laws.
However, the Bush Administration adopted a contrary position that,
state law notwithstanding, any personal possession of marijuana, even
for medical reasons and without any evidence of sale or commercial
purposes, amounted to a criminal violation of the CSA. In effect, the
Bush Administration eliminated its predecessor’s medical use
exception.338

In 2009, in response to growing tension between state decriminalization
efforts and marijuana’s Schedule I status, the Deputy Attorney General
David Ogden issued a policy memorandum, which attempted to resolve
this conflict (the “Ogden Memo”).339
The Ogden Memo reiterated that “the Department of Justice is
committed to the enforcement of the Controlled Substances Act in all
States[,] [that] Congress has determined that marijuana is a dangerous
drug, and [that] the illegal distribution and sale of marijuana is a serious
crime and provides a significant source of revenue to large-scale criminal
enterprises, gangs, and cartels.”340 However, in an effort to “mak[e]
efficient and rational use of its limited investigative and prosecutorial
resources,” the federal prosecution of “significant traffickers of illegal
drugs, including marijuana, and the disruption of illegal drug
manufacturing and trafficking networks [would] continue to be a core
priority.”341 But federal resources would no longer be directed to the
investigation and prosecution of any “individuals whose actions are in
clear and unambiguous compliance with existing state laws providing for
the medical use of marijuana.”342 The Odgen Memo drew a firm
distinction between drug trafficking and distribution and person medical
use as permitted by state law.
The following policy statement from then Attorney General Eric
Holder accompanied the release of the Ogden Memo:
It will not be a priority to use federal resources to prosecute patients
with serious illnesses or their caregivers who are complying with state
laws on medical marijuana, but we will not tolerate drug traffickers

338. Rosenbaum, supra note 329, at 680.
339. U.S. Deputy Att’y Gen., Memorandum on Investigations and Prosecutions in
States Authorizing the Medical Use of Marijuana (Oct. 19, 2009), http://bit.ly/2rCHLFi.
340. Id.
341. Id.
342. Id.
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who hide behind claims of compliance with state law to mask activities
that are clearly illegal.343

At the time of the Ogden Memo, the DEA website included the
following warning: “Smoked marijuana has not withstood the rigors of
science — it is not medicine and it is not safe. [But the DEA] targets
criminals engaged in cultivation and trafficking, not the sick and dying.”344
Years earlier, on August 29, 2013, then U.S. Deputy Attorney General
James M. Cole had released a memo announcing that the Department of
Justice would not allocate any resources to efforts to overturn marijuana
legalization under state law.345
The transition from the Obama administration to the Trump
administration has been accompanied by many policy changes. On
January 4, 2018, then Attorney General Jeff Sessions rescinded the Ogden
Memo and reversed the five-year-old Obama policy346 of non-interference
with states that have decriminalized or legalized marijuana use.347 By
2018, more than half of the states had decriminalized medical marijuana,
and at that time eight states also allowed the possession of small amounts
of marijuana for recreational use.348 The Trump administration’s
announcement came just three days after the legalization of recreational
marijuana in California following a decade of widely available medical
marijuana throughout the state.349
The Trump administration announcement was a reversal, not just of
Obama’s policy, but also of candidate Trump’s specific campaign pledge

343. David Stout and Solomon Moore, U.S. Won’t Prosecute in States That Allow
Medical Marijuana, N.Y. TIMES (Oct. 19, 2009), https://nyti.ms/2EwmLbr.
344. Id.
345. U.S. Deputy Att’y Gen., Memorandum on Guidance Regarding Marijuana
Enforcement (Aug. 29, 2013), https://www.justice.gov/iso/opa/resources/
3052013829132756857467.pdf.
346. See id.
347. See Laura Jarrett, Sessions nixes Obama-era rules leaving states alone that
legalize pot, CNN (Jan. 4, 2018, 5:44 PM), https://cnn.it/2LiQ1TU.
348. See Chemerinsky et al., supra note 84, at 85–89.
349. See Jarrett, supra note 347. Currently, you can purchase marijuana for recreational
use in Alaska, Colorado, the District of Columbia, Maine, Massachusetts, Michigan,
Nevada, Oregon, Vermont, and Washington. See Map of Marijuana Legality by State,
DISA, https://disa.com/map-of-marijuana-legality-by-state (last updated Jan. 2019). A
close vote in Maine, which necessitated the hand counting of individual ballots, resulted in
a January 2017 decision legalizing recreational use. See Gillian Graham, Recreational
marijuana is now legal in Maine. Here’s what you need to know, PORTLAND PRESS HERALD
(Jan. 30, 2017), https://bit.ly/2DteAMz. However, Maine’s then-Governor, Paul LePage,
voiced his opposition a YouTube video predicting that marijuana use would lead to heroin
addiction, would occur next to schools, daycare centers, and churches, and finally that pot
would now be smoked and sold at Maine’s state fairs. See Real High End Glass for Sale,
Maine’s Governor LePage on Question 1, YOUTUBE (Oct. 16, 2016),
https://www.youtube.com/watch?v=Dg9wHovN5FI&feature=youtu.be.
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to leave marijuana-related decisions to the states.350 It is also worth noting
that one month later, Sessions released a memo on private prisons
reversing the Obama Administration’s plan to phase out private prisons.351
To the extent that the Obama-era marijuana policy was intended to help
reduce incarcerations for minor marijuana possession offenses, the Trump
administration’s rescission of this policy would have the opposite effect
creating a crop of new inmates and more profits for private prisons and
their owners.352
Recent Trump administration decisions are not only inconsistent with
campaign promises, but they do not reflect public opinion as shown by
recent political polling data. Currently, 71% of U.S. voters do not approve
of federal government intervention into state decisions decriminalizing
marijuana.353 Current DOJ policy is consistent with Session’s
longstanding personal antipathy towards pot. Before serving as Attorney
General, Sessions was widely-quoted as saying that “good people don’t
smoke marijuana.”354 While serving as Attorney General, Sessions had
sent a letter to Congress warning that state marijuana legalization spawns
the growth of black markets and increases interstate marijuana
commerce.355 Finally, in what sounds too much like Breaking Bad-induced
confusion, Sessions also blamed marijuana legalization for causing
numerous deadly lab explosions.356 Although it is impossible to accurately
predict whether the new Trump policies will result in more prosecutions
and incarcerations, by disrupting the Obama era détente they will
exacerbate tensions between federal and state law and enforcement
objectives.
B.

Recent Federal Legislative Initiatives
1. The Marijuana Justice Act (2017)

A few months before Sessions rescinded the Ogden Memo, Senator
Cory Booker waded into the public debate by introducing the Marijuana
Justice Act of 2017.357 This multi-purpose law offers a radically different
350. See Chris Nichols, TRUE: During campaign, Trump pledged to leave marijuana
legalization up to states, POLITIFACT (Feb. 28, 2017, 6:00 AM), https://bit.ly/2lv5Ton.
351. See Jon Schuppe, Private Prisons: Here’s Why Sessions’ Memo Matters, NBC
NEWS (Feb. 26, 2017, 5:23 AM), https://nbcnews.to/2LgaY1C.
352. Id.
353. See Nichols, supra note 350.
354. See German Lopez, The Trump administration’s new war on marijuana,
explained, VOX (Jan. 5, 2018, 10:35 AM), https://bit.ly/2E9antJ.
355. See Letter from Jeff Sessions, U.S. Att’y Gen., to Jay Inslee, Wash. Governor, and
Robert Ferguson, Wash. Att’y Gen. (July 24, 2017), https://bit.ly/2JPoXuv.
356. Id.
357. See Marijuana Justice Act of 2017, S. 1689, 115th Cong. (2017).
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approach to the same federal vs. state conflict, because Senator Booker’s
proposal would fully legalize marijuana at the federal level.358
In addition to eliminating legal and enforcement inconsistencies,
Senator Booker is specifically focused on broader social justice objectives.
The Marijuana Justice Act seeks to reduce or eliminate the disparate socioeconomic, racial, and ethnic impact of marijuana arrests and prosecutions.
The Act, would “incentivize states through federal funds to change their
marijuana laws if those laws were shown to have a disproportionate effect
on low-income individuals and/or people of color.”359 The Marijuana
Justice Act would involve conditional federal spending and its future
remains uncertain, but its explicit social justice goals would likely received
some congressional support.
2. The VA Medicinal Cannabis Research Act (2018)
On May 8, 2018, a House committee approved cannabis legislation
that would encourage the U.S. Department of Veterans Affairs (the
“V.A.”) to conduct research on marijuana’s medical benefits.360
Specifically, the VA Medicinal Cannabis Research Act of 2018 would
allow and support research relating to the safety and efficacy of marijuana
to treat veterans diagnosed with chronic pain, post-traumatic stress
disorder, and other conditions.361 According to the American Legion,
which is a congressionally chartered Veteran Service Organization, as of
October 2017, over 90% of all veterans surveyed support medical cannabis
research and over 80% of veterans also support legalizing medical
marijuana.362 The American Legion also reported that over 22% of
veterans already use cannabis to treat some type of medical condition.363

358. Id.
359. See Press Release, Sen. Cory Booker, Booker Introduces Landmark Bill to End
the Federal Prohibition on Marijuana (Aug. 1, 2017), https://bit.ly/2f6g18M. Senator
Booker stated:
Arrests for marijuana now account for more than half of all drug arrests in the
U.S., and black Americans too often bear the brunt of these misguided laws.
Blacks are nearly four times as likely to be arrested for marijuana possession as
whites are, despite the fact that there’s no difference in marijuana use between
the two groups.
Id.
360. See Committees: H.R.5520 — 115th Congress (2017-2018), CONGRESS.GOV,
https://www.congress.gov/bill/115th-congress/house-bill/5520/committees (last visited
Mar. 18, 2019).
361. See VA Medicinal Cannabis Research Act of 2018, H.R. 5520, 115th Cong.
(2018).
362. See CHAIRMAN PHIL ROE, H. COMM. ON VETERANS’ AFFAIRS, BACKGROUND TO
H.R. 5520: THE VETERANS AFFAIRS MEDICINAL CANNABIS RESEARCH ACT OF 2018 (2018).
363. Id.
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However, the legislative fate of the VA Medicinal Cannabis Research
Act of 2018 may be irrelevant. In a surprising decision, on July 25, 2018,
the V.A. announced that it would not recommend or even study the use of
medical marijuana to treat veterans.364 The public response was
immediate. The New York Times responded in an op-ed by citing “a
disconnect in care”365 by the Veteran’s Administration. According to the
Times’ editors, the V.A. “has funded lots of marijuana studies, but not of
therapeutic potential. All the work has been related to problems of use.”366
A V.A. spokesman, who failed to address the substantive concern that
abuse merited attention but medical potential did not, simply stated that
the bill did not change marijuana’s current Schedule I status.367
Current VA policy is an abrupt shift away from the position espoused
by Dr. David J. Shulkin, the Trump Administration’s first Secretary of
Veterans Affairs. Dr. Shulkin had specifically recommended that “the
tangle of red tape surrounding Schedule 1 drug studies” be reduced to
facilitate cannabis research.368 According to Dr. Shulkin, medical
marijuana could be especially important to veterans: “We have an opioid
crisis, a mental health crisis, and we have limited options with how to
address them, so we should be looking at everything possible.”369 To date,
the V.A. has not publicly explained the reason for this abrupt shift in policy
or its complete disinterest in exploring marijuana’s potential therapeutic
benefits for the community it serves.
C.

Confounding Political Factors
1. The Opioid Crisis

The opioid addition crisis further complicates marijuana policy. The
recent increases in both medicinal and recreational cannabis use had been
attributed (at least in part) to growing awareness of the significant health
risks of opioid abuse and addiction.370

364. See Dave Philipps, V.A. Shuns Medical Marijuana, Leaving Vets to Improvise,
N.Y. TIMES (July 25, 2018), https://www.nytimes.com/2018/07/25/us/marijuanaveterans.html.
365. Id.
366. Id.
367. Id.
368. Id.
369. Id.
370. See Kevin Murphy, New York Points the Way in Dealing with Opioid Crisis,
FORBES (Aug. 2, 2018), https://www.forbes.com/sites/kevinmurphy/2018/08/02/newyork-points-the-way-in-dealing-with-opioid-crisis/#5e7bf4628f62 (discussing how New
York State’s Department of Health has begun to prescribe medical marijuana as an opioid
replacement).
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The extant data on any possible link between marijuana and opioid
use is inconclusive. The evidence may eventually establish a worrisome
association between marijuana use and opioid use or it may prove that
marijuana is a helpful and effective substitute for opioids for some
palliative purposes and/or that marijuana can be used to limit opioid
reliance.
Recent research suggests that marijuana may form one part of an
opioid crisis solution. In a study presented at the May 2018 meeting of the
American Geriatrics Society, medical marijuana was linked to effective
efforts to curb the opioid overuse—especially for older patients living with
chronic pain from osteoarthritis, spinal stenosis, or pain from hip and knee
joints that could not be replaced.371 Dr. Diana Martins-Welch, a co-author
of the study, stated: “What I’m seeing in my practice, and what I’m hearing
from other providers who are participating in medical marijuana programs,
is that their patients are using less opioids.”372 If others can replicate these
findings, it would incentivize future research into marijuana substitution
for opioid users.
But policymakers, voters, and consumers should not misconstrue a
public push to replace opioids with cannabis as evidence that cannabis is
benign or has no addiction risks. Currently, “public perception
surrounding the use of medicinal cannabis suggests that this plant-based
therapy is viewed as not much different than a botanical drug product or
supplement used for health or relief of symptoms if disease persists.”373
Marijuana is demonstrably safer than opioids; there has never been a
reported death from a marijuana overdose.374 However, as shown above,
the data on marijuana and addiction is incomplete and inconclusive, and
its long- and short-term physiological and psychological effects are
virtually unknown. Given the paucity of the scientific evidence, any
assumption that cannabis must be healthy because it is a botanical, is
ridiculously naive.
2. Scientific Illiteracy,
Relativism

“Truthiness,”

and

Empirical

Good marijuana law must be based on good marijuana science. But
our 50 years commitment to maintaining marijuana as a Schedule I
substance has guaranteed that the stagnant science cannot keep pace with
371. See Northwell Health’s Feinstein Inst. for Med. Res., Survey: Medical marijuana
could reduce opioid use in older adults, MED. XPRESS (May 1, 2018),
https://medicalxpress.com/news/2018-04-survey-medical-marijuana-opioid-older.html.
372. Id.
373. Bridgeman et al., supra note 50, at 181.
374. See Elli Silverman, The Truth Behind the ‘First Marijuana Overdose Death’
Headlines, WASH. POST (Nov. 17, 2017), https://wapo.st/2DRqFu8.
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the changing law. But, as with all other twenty-first century science and
law problems, the lack of evidence is not the only impediment to clear
thinking and sound public policy.
Pro-legalization state legislators seeking new revenue streams have
little interest in demanding more scientific data that could reveal the risks
of marijuana. Their constituents are similarly disinclined to advocate for
more research. When voters support or oppose legalization, they are
unlikely advocates for better research because we are an increasingly
scientifically illiterate population that simply fails to recognize the
unknown information we actually need. Americans have a shocking and
increasing unfamiliarity with fundamental scientific facts and methods
including the relationship between the earth and sun, and cannot answer
basic questions about earth’s history including when humans ever rode
dinosaurs.375 Our scientific ignorance becomes more problematic when
combined with a growing disinclination to question our own beliefs and
instant Internet access to unreliable confirmatory information. As these
sociological factors work together, they are “dramatically reshaping our
relationship to the world of knowledge”376 by “unmoor[ing] information
from the context required to understand it.”377 Once considered inarguable
fact, scientific information is increasingly dismissed as mere opinion.
This relativistic approach to science-based questions raises important
concerns. The philosopher Susan Haack has predicted:
As science progresses, it tends to get more expensive; in part because
many, if not most, of the easily- and cheaply-obtainable results have
been obtained already, and in part, because, as the work becomes more
complex, it also becomes more costly . . . . As scientific work becomes
more expensive, it must rely more and more on governments and large
industrial concerns for support; and these, obviously, are apt to give
priority to quite other values than the epistemological norms at the
heart of the scientific enterprise.378

In the similarly prescient words of Stephen Colbert:
Truthiness is tearing apart our country, and I don’t mean the argument
over who came up with the word. I don’t know whether it’s a new
thing, but it’s certainly a current thing, in that it doesn’t seem to matter
what facts are. It used to be, everyone was entitled to their own

375. See SCIENCEDAILY, supra note 73.
376. MNOOKIN, supra note 74, at 5–8 (describing the promulgation of the increasingly
popular and dangerous myth that MMR vaccines cause autism).
377. Id.
378. See Haack, supra note 76, at 15.
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opinion, but not their own facts. But that’s not the case anymore. Facts
matter not at all. Perception is everything.379

A value-laden or “truthiness” approach to scientific inquiry cannot
produce valid evidence, except by chance.
In the marijuana context, legalization proponents may appeal to a
scientifically ignorant voting public, by touting marijuana as a medical
cure-all or a safe alternative to opioids or alcohol. Voters unsophisticated
about the rigor of scientific research and testing will simply assume they
have adequate information. Under these circumstances, the impetus for
better scientific information can only come from the scientific community.
American scientists hamstrung by marijuana’s Schedule I status and
unable to compete with foreign counterparts have made no headway on
this problem for the past fifty years. It is possible, but far from certain,
that the current massive shift to greater marijuana use will provide
increased evidence of its effects and provoking the federal government to
remove current research obstacles.
I have written elsewhere about the harm that courts cause policy
makers and the public when they engage in extralegal judicial decisionmaking without predicate empirical evidence.380 In the marijuana context,
future decision maker (judges, lawmakers, voters, and consumers) who
seek accurate information about marijuana’s benefits and risks online or
from unreliable media sources will almost invariably be misinformed. In
the context of mainstream “respectable” media, there is a ubiquitous
tendency to present a “balanced” view on virtually every question of
natural or social science.381 In many contexts, this balance falsely suggests
an empirical equivalence–even when the evidence for one side is
overwhelming (e.g., natural selection, global warming, childhood vaccine
safety). For example, the physiological and psychological risks of
marijuana use, especially regular use by adolescents may be significant
and its benefits uncertain. These concerns are not in equipoise. As decision
makers consider marijuana, the mainstream media is not the only problem.
Although we typically turn to medical and scientific published for valid
evidence, a shocking number of medical and scientific articles are
published without critical information, including authors’ conflicts of

379. Nathan Rabin, Interview: Stephen Colbert, A.V. CLUB (Jan. 25, 2006, 1:26 PM),
http://www.avclub.com/article/stephen-colbert-13970.
380. See generally Joelle A. Moreno, Extralegal Supreme Court Policymaking, 24 WM.
& MARY BILL RTS. J. 451 (2015).
381. See Katrina vanden Heuvel, The distorting reality of ‘false balance’ in the media,
WASH. POST (July 15, 2014), https://wapo.st/1opwv8e (describing the problem of “[f]alse
equivalence in the media [and] giving equal weight to unsupported or even discredited
claims for the sake of appearing impartial . . . .”).
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interests.382 Thus, sources of information can educate or contribute to
confusion and bad decisions.
Finally, the future of evidence-based marijuana decision making is
threatened by the problems that arise based on incomplete information. All
science-based law and policy questions require that decision makers
accept or reject arguments about causation. Dr. Frank C. Keil, Director of
the Yale Cognition and Development Lab, has found that decisions about
causation based on incomplete information can be especially problematic
because “[p]eople of all ages tend to be miscalibrated with respect to their
explanatory understandings; that is, they think they understand in far more
detail than they really do how some aspect of the world works or why some
pattern in the world exists.”383 In order “[t]o assess how well people deal
with causal complexity . . . one must first know when one is in over one’s
head.”384 Marijuana decision makers operating without an extant base of
valid scientific evidence will need better methods “of sensing when there
are gaps in one’s knowledge that make one’s understanding so flawed that
it is inadequate for use in a task.”385 Like the problems that arise when
decisions about science are made by the scientifically ignorant, this
involves the near-impossible tasks of recognizing deficits in information
and understanding.
Although not a panacea, decision-making research from behavioral
economics could prove helpful. Professor Brendan Nyhan of Dartmouth
College has examined the impact of providing accurate scientific
information to parents deciding whether to vaccinate their children.386
Professor Nyhan’s research showed that parents with mixed or negative
feelings toward vaccines who were provided with accurate information
about medical benefits and risks paradoxically “became less likely to say
they would vaccinate a future child after receiving information debunking
the myth that vaccines cause autism.”387 Given the obstacles to developing
a more accurate and comprehensive scientific data on marijuana’s
physiological and psychological effects, Professor Nyhan’s research
suggests that the evidence is not enough. To facilitate the development
382. See Curtis Brainard, Mixed Grades for Medical Coverage, COLUM. JOURNALISM
REV. (Apr. 22, 2011), http://www.cjr.org/the_observatory/mixed_grades_for_med_
coverage.php?page=all.
383. Frank C. Keil, Explanation and Understanding, 57 ANN. REV. PSYCHOL. 227, 242
(2006).
384. Frank C. Keil, Getting to the Truth: Grounding Incomplete Knowledge, 73 BROOK.
L. REV. 1035, 1037 (2008).
385. Id.
386. See generally Brendan Nyhan et al., Effective Messages in Vaccine Promotion: A
Randomized Trial, 133 PEDIATRICS 835 (2014).
387. Brendan Nyhan, Vaccine Opponents Can Be Immune to Education, N.Y. TIMES
(May 8, 2014), https://nyti.ms/2Dd06zF (emphasis added).
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science-based public policy, presentation of future data (or data from
overseas) must be accompanied by information designed to accommodate
conscious and unconscious emotional reactions to marijuana use as a
medicine or palliative, or for recreation. If marijuana is not removed from
Schedule I, marijuana research will likely only proceed in narrow areas of
research reflecting public health priorities. The best example is the June
2018 FDA approval of the CBD-derived drug (Epidiolex) to treat pediatric
epilepsy.388
The current rush towards state marijuana legalization raises
interesting and vital new science-based legal questions and resulting
policy decisions will redound beyond the pot-smoking/vaping/eating
electorate. As with every science-based social question, our “democratic
society depends on the ability of its members to make rational choices . . .
. [and] [i]f we can’t tell the difference between reasonable and
unreasonable claims, we become susceptible to the claims of charlatans,
scoundrels, and mountebanks.”389 As a 2017 Harvard/National Science
Foundation study recently warned, if Americans continue to approach new
empirical questions with “[m]isperceptions about the scientific and
political world,” as a 2017 Harvard/National Science Foundation study
recently warned, these questions will aggregate and “pose a fundamental
threat to democracy, undermining citizens’ ability to make decisions that
effectively promote both individual self-interest and the social good.”390
The rapid legalization of medical and recreational marijuana does not end
the science-law debate. Instead it is the first step in a decision chain
implicating the reach of national drug policy, the depth of state
sovereignty, and how we will fulfill our shared obligation to ensure the
health and safety of our citizenry.

388. See FOOD & DRUG ADMIN., supra note 216; see also Wells, supra note 98.
389. Homayun Sidky, The War on Science, Anti-Intellectualism, and ‘Alternative Ways
of Knowing’ in 21st-Century America, SKEPTICAL INQUIRER, Apr. 2018, at 38, 38.
390. R. Kelly Garrett & Brian E. Weeks, Epistemic beliefs’ role in promoting
misperceptions and conspiracist ideation, PLOS ONE, Sept. 18, 2017, at 1, 1.

